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Cancer is a leading cause of death worldwide. Unlike its name would suggest, cancer is not a
single disease. It is a group of diseases that arises from the expansion of a somatic cell clone.
This expansion is thought to be a result of mutations that confer a selective advantage to the
cell clone. These mutations that are advantageous to cells that result in their proliferation and
escape of normal cell constraints are called driver mutations. The genes that contain driver
mutations are known as driver genes. Studying these mutations and genes is important for
understanding how cancer forms and evolves.
Various methods have been developed that can discover these mutations and genes. This
thesis focuses on a method called Deep Mutation Modelling, a deep learning based approach to
predicting the probability of mutations. Deep Mutation Modelling’s output probabilities offer
the possibility of creating sample and cancer type specific probability scores for mutations that
reflect the pathogenicity of the mutations. Most methods in the past have made scores that
are the same for all cancer types. Deep Mutation Modelling offers the opportunity to make a
more personalised score.
The main objectives of this thesis were to examine the Deep Mutation Modelling output as it
was unknown what kind of features it has, see how the output compares against other scoring
methods and how the probabilities work in mutation hotspots. Lastly, could the probabilities be
used in a common driver gene discovery method. Overall, the goal was to see if Deep Mutation
Modelling works and if it is competitive with other known methods.
The findings indicate that Deep Mutation Modelling works in predicting driver mutations, but
that it does not have sufficient power to do this reliably and requires further improvements.
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Cancer is one of the leading causes of death in the world and its incidence is expected to
grow [53]. In 2020 cancer caused nearly 10 million deaths in the world and further 19.3
million cases were diagnosed [49]. In 2018 cancer caused 12,730 deaths in Finland. In
Finland it is estimated that 36% of women and 38% of men will get cancer during their
lifetimes [37]. Cancer however is not a single disease but rather a group of diseases with
a similar origin of uncontrolled expansion of a somatic cell clone. The somatic cell clone
starts to proliferate when it gains mutations that confer a selective advantage to this cell
clone over other cells in the tissue and the cell clone manages to evade normal immune
surveillance. The mutations that confer the selective advantage are known as driver muta-
tions and genes which contain these driver mutations are known as driver genes. As cancer
cells accumulate numerous mutations not all of them can be driver mutations and some
of them are instead passenger mutations that are selectively neutral. [29]. It is currently
thought that all cancers originate from cells that have driver mutations in them. However,
it is currently unclear how many driver mutations there are and how many are needed
for tumorigenesis [26]. Currently it is thought that there are relatively few recurrently
mutated driver mutations and many more much rarer driver mutations [10]. Additional
questions arise from the specificity of driver mutations in different tumour types. Some tu-
mours have recurrent mutation patterns while others have more interchangeable mutations
in their key signalling pathways [14].
There have in the past two decades been several large-scale projects which have sequenced
genomes from tumours. Two of such projects are the Pan-Cancer Analysis of Whole
Genomes (PCAWG) [53] and The Cancer Genome Atlas (TCGA) [33]. The PCAWG
project is an international collaborative project intended to discover common patterns of
mutations from over 2,600 different tumour samples. The data in PCAWG project is based
on International Cancer Genome Consortium whole genomes [53]. The TCGA project is a
collaborative cancer genomics project between the National Cancer Institute and National
Human Genome Research Institute. The program has produced different publicly available
data on cancer including exome, the coding regions of the genome, sequence data and data
on the somatic mutations present in the tumour samples [33].
There have been multiple different methods that have been used to identify driver muta-
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tions and driver genes. In these studies, if there were mutations that had higher recurrence
than expected they were generally classified as driver mutations [39]. The occurrence of
driver mutations should differ from the background mutation rate as driver mutations are
under positive selection while the background mutation rate should reflect the conditions
under neutrality. For example, recurrence of a mutation in multiple tumour samples in a
sequenced cohort can be a sing of positive selection [29].
Recently there has also been interest in using deep learning methods to identify driver
mutations [24, 2]. Deep learning is a sub-field of machine learning that focuses on repre-
sentation learning, where a system can be given raw data and it can automatically discover
important features from this raw data on its own. Traditional machine learning methods
are at a disadvantage compared to deep learning in that they have limited capabilities
of processing the raw data and require human interference for the discovery of important
features. The discovery of the important features by humans, however, requires signif-
icant domain knowledge and may still miss features that could be discovered from the
data. Representation learning works by transforming the input with non-linear functions
into more abstract representations that can be combined to classify data. In image data
representation learning can for example mean that the system learns that there are edges
in the image and the edges form shapes when they are combined. This allows the system
to learn complex features and allows for the suppression of unimportant information [20].
Supervised learning is the most common form of machine learning and this applied to deep
learning too. The other common type of machine learning is unsupervised learning. In
supervised learning the model uses input which consists of either features or raw data, and
a target value. Supervised learning is mostly used for classification tasks where the model
tries to predict the target values. In unsupervised learning the model does not use the
target values and instead it tries to group together similar inputs based on their features.
Supervised learning is useful for classification and unsupervised learning is useful for clus-
tering and discovering groups within the data [20]. Both supervised [2] and unsupervised
learning have been used previously in the discovery of driver mutations and genes [19].
This thesis focuses on the exploration of the output, and potential use, of a deep learning
method for modelling mutation probabilities called Deep Mutation Modelling (DMM) [8].
DMM is a deep learning based method that uses raw DNA sequences, which contain
mutations, and sample information as its input. As it is a deep learning based method it
should learn the genomic contexts of the mutations. It attempts to predict which mutation
has occurred in the input sequence. The predicted probabilities of mutations form the
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output. The output of DMM is potentially useful in the discovery of driver mutations and
genes as it could be used as a scoring system for mutations [8]. These types of different
scores have been developed for mutations before and they generally measure either the
functional impact of the mutations or the possible pathogenicity level of them [46] [42].
Combined Annotation Dependent Depletion (CADD) [42] is one such commonly used tool
which scores the deleteriousness of single nucleotide variants. CADD itself is based on the
annotation differences between simulated mutations and alleles which have been fixed in
the human genome since the human-chimpanzee divergence [42]. These types of scores are
used to rank the mutations according to their potential pathogenicity or they can be used
in other methods in aiding the discovery of driver genes [32]. However, these scores are
usually the same for every cancer type and patient. DMM’s output on the other hand is
tumour sample specific and thus could be more flexible than existing scoring systems. This
would allow for a more personalised medicine approach in discovering which mutations or
genes are significant in an individual tumour sample. As the outputs of DMM are sample
specific they can also be combined by cancer type or by some other sample feature to form
specific scores for the feature in question.
This work had several objectives. The first one was to explore the basic features of the
DMM output, the second was to compare the DMM output against other known scoring
systems for mutations, the third was to see how the DMM output works with hotspot
mutations, and lastly to see if the DMM outputs can be used in a previously established
method of driver gene discovery as the scoring system for mutations. The main objective
was to see if DMM works as intended and to see if it is competitive with other methods
that have been used before.
I first explored single nucleotide variant datasets from the PCAWG and TCGA projects
and the outputs that DMM produced for them. After this I compared other functional
impact and pathogenicity score datasets with DMM for the PCAWG and TCGA muta-
tions. The other score datasets used contained this information for non-synonymous, or
synonymous, or both types of mutation depending on the dataset in question.
After exploration of the DMM output, I tested if the output could be used in a driver gene
detection method known as OncodriveFML [32]. OncodriveFML computes how significant
a gene is based on its observed mutation distribution versus a generated distribution. For
this OncodriveFML needs a score file from where it can extract scores for the computations.
[32] I used the DMM output to construct score files for four cancer types from the PCAWG
and TCGA datasets. I compared these with the CADD score, which is the same for every
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tissue type. In the analysis I used four known cancer genes APC, BRAF, KRAS, and
TP53 and six other genes.
The first chapters of this thesis focus on giving an overview of natural selection in cancer
and background mutation rates in cells. After this the thesis covers the types of driver
mutations present in cancer genomes and how these driver mutations and driver genes
have been discovered in the past. The thesis will then move on to the experimental
section which contains exploration of the DMM model’s output and comparison to other
scoring schemes that can be used to assess the impact of mutations. The experimental
section also contains an experiment done by using the DMM output in OncodriveFML.
2 Background
2.1 Basic types of mutations
Cancer cells gain mutations stochastically through mutagens or DNA replication errors.
Most of these mutations are passenger mutations which generally do not change the func-
tionality of the cell. A small minority of the mutations give an advantage to the cells
which allow them to escape the growth restraints on somatic cells. These cancer cells then
end up proliferating. The mutations that provide a selective advantage to the cancer cells
are known as driver mutations [53]. Mutations can be classified also into germline and
somatic mutations. Germline mutations can be passed onto the next generation and they
affect every cell in an individual’s body causing a change in the genotype. Somatic refers
to the non-germline cells that will also accumulate mutations over time, but they cannot
be passed onto the next generation within the species [25].
Cancer causing genes can generally be classified into two groups: oncogenes and tumour
suppressor genes. Oncogenes generally drive cancer by a gain of function mutations where
the expression of the oncogene is increased or the protein it codes for changes into one
that can cause cancer. Tumour suppressor genes tend to work in the opposite way where
the cancer-causing mutations tend to inactivate the gene either by changing the regulatory
regions or by making the protein product non-functional [5].
Mutations in the coding region of the genome, which makes up approximately 2% of the
human genome [1], can alter the amino acid chain the genes code. The effects of non-
coding mutations are harder to study as they do not alter the protein structure which
makes their effects harder to detect. Non-coding mutations may affect the regulatory
elements and processes present in the genome. Studying these mutations is difficult due
to the still lacking knowledge on the functionality of the non-coding regions [43].
Single nucleotide variants (SNV) refer to variants of a single nucleotide. Single nucleotide
variants can for example be single nucleotide substitutions [48]. Nucleotide substitutions
can be classified into transversion and transitions. Transversions happen when substitu-
tions result in a pyrimidine base, C and T, being replaced by a purine base, A and G, or
vice versa. Transitions happen when a purine base is replaced by a different purine base
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or when a pyrimidine base is replaced by another pyrimidine base [12]. Within the exome
these mutations may act as missense, synonymous, or nonsense mutations. Missense mu-
tations change the amino acid the codon triplet codes to another one. These mutations
may also not result in a change in the amino acid in which case the mutations are known
as synonymous mutations. Non-synonymous mutations can also cause the formation of
an early stop codon truncating the protein. These truncating mutations are known as
nonsense mutations [48]. Mutations may also cause a change in the protein if they cause a
disruption in the splice sites near the exon-intron boundaries [50]. Within the non-coding
genome SNVs can alter the binding motifs of different molecules or they may create new
binding motifs [40]. A similar concept to SNVs is single nucleotide polymorphism (SNP)
which refers to there being at least two alternative bases present in a population in a single
locus in the genome [48].
Short insertions or deletions of nucleotides are called indels. As with substitutions indels
can cause the protein structure to alter because of amino acid change or due to truncating
of the sequence. Within the coding regions an indel, which length is not a multiple of
three, may also cause a frameshift in the sequence altering the sequence following the
mutation. A frameshift causes all following codon triplets to change. If the indel length is
a multiple of three then it causes either the insertion of new amino acids or the deletion
of them. Larger changes in the genome are called either copy number variants, variation
between individuals in the number of over 50, base pairs long DNA sequences, or structural
variants, changes that are longer than 50 base pairs. Inversions or translocations of DNA
are, for example, examples of structural variants [48].
2.2 Natural selection in cancer
Natural selection is the driving force behind evolution. While natural selection is usually
applied on species it does also apply to cancer cells. As such cancer follows Darwinian
model of evolution. In the formation of a tumour cancer cells compete against the envi-
ronment created by normal cells and if they manage to gain a competitive edge, they will
form a tumour [53]. Natural selection can be classified into positive and negative selection.
Positive selection occurs when a mutation gives a selective advantage to the organism and
this genotype becomes the dominant one within the population. Negative selection on the
other hand removes deleterious alleles from the population, in this case the organism has
fewer offspring than its competitors leading to the disappearance of the deleterious allele.
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In the case of cancer positive selection will result in the cancer cell proliferating. Negative
selection in cancer would lead to the death of sub-clones due to deleterious alleles [27].
A major gap in understanding cancer is that it is unknown how many mutations are nec-
essary for cancer formation [26]. One way to do this would be to count the mutations
occurring in the known driver genes, but this is difficult because not all driver genes are
known and the presence of passenger mutations in these genes would make this difficult.
However, the number of non-synonymous base substitution driver mutations within tu-
mours is estimated to be withing 1 to 10 range with the average being 4. Another gap
in understanding is the lack of knowledge regarding negative selection in cancer evolution
and to what extent do somatic lineages die off due to effects of deleterious mutations. De-
tection of negative selection is important because as it may help identify new driver genes
and patterns of synthetic lethality. [27] Additionally, normal mutational burden in normal
somatic cells is one of the unanswered questions in cancer. Other important questions are
which mutation processes are operative in normal cells, the pattern of clonal expansion
caused by first drivers, and the positive selection of competing clones within an organ. It
has for example, been found that known driver genes can be under positive selection in
normal tissue without there being a malignant tumour [28].
Genes under negative selection are expected to have lower number of mutations than would
be expected under neutrality. Similarly, a gene under positive selection in cancer would
have more driver mutations than expected. One common way of studying the number
of mutations under selection is to compare the number of non-synonymous mutations in
genes against the number of synonymous mutations. This is known as the dN/dS rate.
The assumption with this rate is that the synonymous mutations are a good proxy for
the background mutation rate. [27] Under neutrality the rate should be approximately 1,
while rates greater than 1 indicate positive selection and rates under 1 indicate negative
selection [54]. dN/dS rates have traditionally been used in population genetics to study
species evolution, but it is also possible to use it in somatic cells. The use of dN/dS rate in
somatic cells however requires adjustment so that it is more sensitive to more than simple
missense mutations, the different mutation rate in different genes and possible presence of
germline mutations. [27]
It is estimated that normal somatic cells gain 2 to 10 new mutations in their diploid
genome in every cell division and that normal cells will accumulate somewhere between a
hundred and a few thousand substitutions [26]. Genome wide dN/dS rates in normal cells
when looking at germline mutations show that the rate is very low. In common human
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germline polymorphism, the rate is around 0.08 dN/dS. Accordingly, negative selection
characterises species evolution. Cancer evolution, however, generally shows genome wide
dN/dS ratios a little above 1. This applies to multiple cancer types and applies to both
missense and truncating mutations. Similar rate is also found from somatic mutations in
healthy tissues. This means that in cancer mutations are under slight positive selection,
but overall, the selection is close to neutrality. Thus, dN/dS ratio of approximately 1
characterises evolution in healthy somatic tissue and cancer. In hypermutated tumours
the dN/dS ratio converges towards 1 and the number of driver mutations increase but
with diminishing numbers as the mutation burden increases as most of the mutations are
still passenger mutations [27].
Healthy tissues can exhibit similar patterns of mutations and selection as cancer cells.
Healthy skin that has been exposed to UV-light has the same predominance of C→T and
CC→TT mutations as skin cancers do. The same applies to C→A substitutions that are
often seen in cutaneous squamous cell carcinoma cancers. Known cancer associated genes
can additionally show positive selection even in healthy tissue. For example, a dN/dS
analysis of UV-exposed skin showed that several genes belonging to the NOTCH group
had excesses of protein-altering base substitutions. NOTCH receptors play a part in stem
cell regulation and are often targets of inactivating mutations in epithelial cancers and
activating mutations in lymphoid malignancies. NOTCH1 is often inactivated in both
alleles in squamous cell carcinomas, but this same inactivation can also be present in
healthy skin so this is not only limited to cancers. In addition TP53 was also identified
as having driver mutations and KRAS was identified as having known canonical hotpot
mutations in it even in this healthy skin. Overall, healthy skin was estimated to have on
average 0.27 driver mutations while cutaneous squamous cell carcinoma tumours would
have an average of 2.7 driver mutations [28]. Driver mutations can also be found from
the blood cells of 10% of individuals older than 65. This mutation pattern is typical
for leukaemia and these individuals have an elevated risk of getting cancer later in life
[26]. And while sub-clones in healthy tissue can carry a few driver mutations this does not
necessarily lead to malignancy. As such the question remains on what events are necessary
for cells to turn malignant [28].
Some reasons for why cancer cells have a high tolerance for deleterious mutations could be
that having two or more copies of genes protects against the deleterious effects. Alterna-
tively, there may be alternative cellular pathways for the same process. Weakly deleterious
mutations can hitchhike with driver mutations, so they become fixed in the cancer pop-
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ulation as the more positive effects of the driver mutation masks the deleterious effects
[27].
2.3 Background mutation rate in normal and cancer
cells
Background mutation rate refers to how often a genomic site mutates. The rate can
vary between different regions within the genome. Mutation rate can be used to estimate
evolutionary distance and it can be used to reconstruct phylogeny and earlier stages of
evolution. As such it is an important feature in understanding the evolution of organisms.
It is also helpful in understanding cancer and cancer evolution. Cancer is a disease that
can be caused by multiple different loci mutating. If certain loci mutate more often then
there are more opportunities for the disease to manifest. On the other hand, it is easy
to mistake sites and genes that mutate often with disease causing variants even if their
effects are neutral. Most of the work on mutation rate has focused on germline mutations
while some work has also examined the mutation rate of somatic mutations in cancer cells
[12].
Within cancer histone modifications and chromatin openness are important factors in-
fluencing the background mutation rate. Many features that affect the mutation rate in
the germline also affects the rate of somatic mutations in cancer [45]. Different cancer
types can have different mutation patterns and be affected by different epigenomic fea-
tures leading to different mutation rates. Up to 86% of the variance in mutation rate in
cancer genomes can be explained by chromatin accessibility, modification, and replication
timing. The best epigenomic features for assessing the local mutation density are features
from the original cell type rather than the cancer cell lines [38] .
Background mutation rate is also dependent on the cancer type, sample and even region
within the sample. Different cancer types have different whole genome mutation rates.
Stomach cancer can have a mutation rate of 11.4 mutations/Mbp whereas medulloblas-
tomas can have a mutation rate of 0.01 mutations/Mbp. Stomach cancers thus can have
800 times higher mutation rate. Even within the same cancer type the mutation rate may
be different between samples. In breast cancer samples the mutation rates vary between
0.36 mutations/Mbp and 21.8 mutations/Mbp [23].
There are several causes that likely explain some of the reasons for the different mutation
10
rates. Regions that replicate later accumulate more DNA damage resulting in more mu-
tations. Methylation pattern in the germline in certain sites may also play a part in the
mutation rate as methylated cytosines in CpG sites are often unstable and may undergo
deamination and change into thymine. This results in a C→T transition and this may ex-
plain why CpG sites and non-CpG sites have a different mutation rate. CpG sites can have
30 times the transition mutation rate compared to other sites in great apes. Transversion
is also more common at CpGs. CpG islands are areas where there is an excess of CG
dinucleotides within approximately 1kb region. These sites are often unmethylated and
thus have a lower substitution rate for CpGs compared to CpGs outside CpG islands. The
stability of the methylated cytosine within a CpG seems to also increase with the CG
richness of the sequence and as a result the mutation rate may be up to three times lower
with these CpG compared to the rest of the genome. Cancer genomes also show evidence
of this CpG effect. [12].
Mutational context is also an important factor in mutation rate within the germline and
the effects vary across the human genome. The importance of adjacent nucleotides effect
on the mutation rate reduces the further away they are from the mutated site [12]. Nu-
cleotide context is also an important factor in the mutation rate of somatic mutations in
cancer. In a pan-cancer analysis of known 520 cancer genes the mutability is higher for
those codon substitutions that were observed within the tumour samples, mean 3.9e-6.
These observed mutations accounted only 1% of the theoretically possible substitutions.
The mutability of substitutions that were not observed were three times lower according
to the background model used, mean 1.3e-6. Both codon and nucleotide mutability were
also higher for synonymous mutations, nucleotide mutability mean 3.9e-6, compared to
the mutability of missense, nucleotide mean 3.2e-6, and nonsense mutations, nucleotide
mean 3.10e-6 [5]. Additionally, there is evidence for context-independent mutation rate in
the germline at certain sites. It has been observed that SNPs occur more often at orthol-
ogous [12], a gene inherited from a common ancestor that has since diverged [48], sites in
humans, chimpanzees, and macaques than is expected if the process was random. This
same pattern is also observed with single nucleotide substitutions between closely related
species. The excess of coincident SNPs and coincident single nucleotide substitutions is
seen in transversions and especially A→T transversion. These sites are not associated
with ancestral variation, difference in sequencing coverage, or selection and such seem to
be hypermutable on their own. Such sites could be influenced by motifs some distance
away from the site that may influence the mutation rate in it [12].
11
Mutation events are also not always independent of each other. Passenger mutations may
be generated by driver mutations as a side effect. This can happen if the driver mutation
happens in DNA replication or repair gene. This causes DNA to accumulate mutations
that may have been otherwise repaired. Within the germline the rate of point mutations
also increases near sites that have undergone insertion or deletion. The effect is strongest
near 50bp on either side of the indel while the effect can still be observed over a few hundred
base pairs. Even very short indels with a length of only a few base pairs have an effect but
the effect of longer indels is stronger. It has been estimated that the mutation rate around
indels might be sixfold in humans [12]. There are also somatic mutation processes that
can generate multiple mutations in one event. Double-stranded DNA breaks can result in
the rearrangement of the DNA even between chromosomes. Kataegis is a hypermutation
process that results in locally clustered nucleotide substitutions. Kataegis is common in
cancers and in a pan-cancer analysis of tumour genomes 60.5% of all cancers had it. Lastly
chromotripsis is a process where hundreds of DNA breaks occur simultaneously in one or
a couple of chromosomes and the fragments are arranged together near randomly. In the
same pan-cancer analysis chromotripsis regions overlapped with 3.6% of identified driver
mutations [53].
Aside from variation of mutation rate within smaller regions there is also larger scale
variation within the chromosomes within the germline. Some of the differences could be
due to selection but an estimated 3% of the intergenic and intronic human genome is
thought to be under selection. Some causes for this variation are replication time, male
recombination rate, distance from the telomeres, CG content, nuclear lamina binding sites,
and simple repeat content. None of these factors explain the differences in mutation rate
between regions alone, but replication time and distance from the telomeres are thought
to be more influential than the others. Chromosomes also have differing mutation rates
[12].
Somatic mutation rates measured from cancer genomes correlate moderately with those
inferred from human-chimpanzee sequence divergence in the germline. On the mega base
scale mutation rate depends strongly on chromatin organisation levels. Euchromatin and
inaccessible heterochromatin especially affect the mutation rate. In cancer it is known that
the highest mutation rates are in the inaccessible heterochromatin like regions and lowest
in euchromatin like regions. single nucleotide variant density is positively correlated with
histone H3K9me3 modification and negatively associated with features that are associated
with open chromatin. In cancer cells H3K9me3 could account up to 40% of the variance in
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single nucleotide variant density [45]. There are some differences in which histone marks
affect which cancer type. Mutation density in hepatocytes follow H3K4me1 levels for
example, while melanocyte mutation rate follows H3K4me1 levels [38].
Interestingly it seems that the epigenomic features of the original healthy cell lines are
better at predicting the mutation density rather than the epigenomic features from cancer
cell lines. This applies at least to liver cancer and melanoma. It is possible that this
is because the somatic mutations arise before the epigenomic changes associated with
tumour progression or the tumour undergoes epigenetic changes later that differ it from
other tumours of the same cancer type. Thus, it is important to consider the cancer type
when investigating the mutation rate within tumour genomes [38].
2.4 Driver Mutations
Driver mutations are mutations that give a growth advantage to a somatic cell clone lead-
ing to clonal expansion and tumour formation. Driver mutations can be challenging to
find as not all mutations in a tumour are driver mutations and instead most are passen-
ger mutations. A pan-cancer analysis of 2658 whole tumour genomes found that 91% of
tumours had at least one driver mutation. On average the tumours had 4.6 driver muta-
tions. On average there were 2.6 coding point mutations per tumour. In the same analysis,
13% of point mutations were non-coding, and 25% of tumours had a potential non-coding
driver mutation [53]. The number of driver mutations is also dependent on the cancer
type in question as the estimated number of driver mutation varies between one and ten.
Endometrial cancers have an estimated little above 10 driver mutations while Thyroid
cancer has approximately 1 driver mutation. Many other cancer types fall between these
numbers [27].
Most studies on driver mutations have focused on protein altering driver mutation within
the coding region but there have also been studies into the non-coding regions [43] and
into synonymous mutations within the coding region [46]. Studying the driver mutations
in these regions is however still challenging due to the poorer understanding of the back-
ground mutation processes and functionality of the non-coding genome. One known target
of non-coding driver mutations is the promoter of TERT gene [43].
A prevailing theory on driver mutations is that there are a small number of highly recurrent
driver mutations, and a larger number of rare driver mutations that are rarely recurrent.
These rare driver mutations form a so called long-tail of driver mutations. These long-tail
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mutations are much harder to detect as they are likely to be cancer type specific and
current tumour genome datasets are possibly too small to detect them if we are detecting
driver mutations by observing the number of recurrent mutations [10].
While the number of driver mutations present in the tumours is an interesting question
another interesting question is how cancer type specific are the driver mutations. Different
cancer types tend to accumulate mutations in different cancer genes. For example, breast
cancer and melanoma tend to have mutations accumulate in tissue-specific genes whereas
lung cancer has a more diffuse mutation pattern [14]. Some driver genes, such as TP53,
are active in multiple different cancer types while other genes are much more specific.
For example, MYC is active in Burkitt lymphomas. Individual tumours even within the
same cancer type can have different mutation profiles. Breast adenocarcinomas can have
mutations in hundreds of genes, or they may only have mutations in only a couple of
handfuls of genes [29]. Different types of driver mutations are also present in different
quantities in different tumour types. Structural variants are more common in breast
adenocarcinomas, mean 6.4 structural variants versus mean 2.2 point mutations, whereas
point mutations are more common in colorectal adenocarcinomas, mean 2.4 structural
variants versus mean 7.4 point mutations [53].
Driver mutations have not been identified in all tumours. The reason for this could be
either technical or biological. Technical issues could arise from poor quality samples, se-
quencing errors or failures in the algorithms used in detecting driver mutations. Biological
causes could include yet unknown driver mutations. Chromophobe renal cell carcinoma
and pancreatic neuroendocrine cancers have been identified as cancer types with high
fractions of patients with no detected driver mutations. A total of 5.3% tumours had no
known driver mutations in a pan-cancer analysis of somatic mutations [53].
Non-synonymous driver mutations
The most common way of discovering driver mutations and genes is to search the coding
regions of the genome for recurrently mutated genes in a tumour sample cohort. Some
common assumptions regarding coding region mutations are that if they affect functionally
important amino acid residues then they are likely more deleterious. Functional impact
of amino acid residues is usually inferred from evolutionary conservation and protein do-
main analysis [21]. Long-tail driver mutations are harder to detect than highly recurrent
mutations. They can potentially be identified is by considering recurrence of mutations
in clusters of spatially close residues in proteins instead of only in linear sequences. They
14
could, for example, be found by looking for missense mutations that cluster together in
3D proximity in protein structures above expected background rate [9].
Non-synonymous mutations are mutations that cause an amino acid change within the
amino acid chain. These can be either missense, nonsense, or indel mutations. Genes
known to be targets of non-synonymous mutations are for example BRAF, APC, TP53
and KRAS. Cancer genes are generally classified into oncogenes and tumour suppressor
genes. Oncogenes and tumour suppressor genes have different pattern of somatic muta-
tions. Tumour suppressor genes have an excess of inactivating mutations and oncogenes
have mutations near specific amino acid residues [36]. This is because tumour suppressor
genes cause cancer by being inactivated and oncogenes by becoming more active or by
changing the protein, they code into an oncogenic one [5]. Analysis of mutations within
cancer genomes have found that recurrent missense mutations have a recurrence rate of
around 29.1%. Missense mutations often target highly conserved sites within genes, and
they are also enriched in charged amino acids compared to non-charged amino acids [46].
Tumour suppressor genes are generally affected by different types of inactivating muta-
tions. TP53 is somewhat different from the usual pattern of tumour suppressor genes as it
is often inactivated by missense mutations. Exons 4 to 9 are especially common locations
of the driver mutations as they contain the coding sequence for the binding site of the p53
protein. The main effects of the various TP53 mutations is that it results in p53 being
unable to bind to its targets. APC is a more typical tumour suppressor gene in that it
is more likely to be inactivated by a deletion or a nonsense mutation [44]. A potential
tumour suppressor gene which may contain rare driver mutations is PTEN. Rare driver
mutations are unlikely to be recurrent and instead they may cluster within certain do-
mains in proteins. For example, a 3D analysis of these kind of clusters found that PTEN
had 15 clusters in it that may fit this profile. The clusters were within the flanking regions
surrounding a phosphatase catalytic core motif, which is necessary for PTEN activity. [9]
In some cases, tumour suppressor genes can have mutations in both alleles disabling them
both. In a pan-cancer analysis of somatic mutations, TP53, had both alleles mutated
in 77% tumours that had driver mutations in the gene. 96% of these two-hit events in
TP53 had a somatic point mutation in one allele and a deletion in the other one. Other
cancer predisposition genes in the same analysis were hit by biallelic inactivation due to
protein-truncating germline mutation and a somatic mutation in 4.5% of the patients [53].
Li-Fraumeni syndrome is a cancer predisposition syndrome where most families with this
disorder have an underlying TP53 germline mutation. Families with missense mutations
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in the TP53 core DNA binding domain have higher incidence and earlier onset of cancer
in comparison to families with other types of mutations in TP53 [44].
Microsatellite instability (MSI) is a type of process that leads to the accumulation of large
numbers of indels in the genome. It is typical to some cancers such as colorectal and
endometrial cancers where MSI is present in 15% of the tumours. Germline mutations in
DNA mismatch repair genes predisposes individuals to these cancers. BRAF and KRAS
have also been implicated as driver genes in MSI cancers. Additionally genes CTNNB1
and PIK3CA are mutated in 1.6% to 4.7% of MSI colorectal cancers, and over half of the
mutations in them tend to accumulate in hotspots. All of these genes have been identified
to have driver point mutations in MSI colorectal cancers [18].
Approximately 50% of skin cancers have TP53 mutations. Different skin cancers types
have different TP53 hotspot mutations, but they all have arginine codon 248 mutation
in common. In UV-induced skin cancers these mutations seem to form early, and they
can drive the formation of precancerous lesions [44]. Another commonly mutated driver
gene in melanoma skin cancers is BRAF. 50% of melanomas have a V600 mutation in this
gene. Another common driver gene for melanomas is NRAS. The V600 mutation in BRAF
and mutations in NRAS are generally mutually exclusive in melanoma. Melanomas have
driver mutations in other genes too. One driver mutation in the RAC1 gene in melanomas
is a c.85C>T transition that results in P29S amino acid change. This gene plays a part in
cytoskeleton rearrangement and by extension cellular adhesion, migration, and invasion.
The prevalence of this mutation is estimated to be 3.9% in melanomas. Its predicted
effect is that it leaves RAC1 in an active, GTP-bound state. Normal RAC1 switches
between active GTP-bound and inactive GDP-bound states. The common BRAF and
NRAS mutations in melanoma do not conform to the common UV-light induced pattern
of C→T mutations, but this RAC1 mutation could be a mutation induced by UV-light
damage [13]. RAC1 has another activating mutation at A159. This gene has also been
identified to have two potential rare driver mutations in the same residue as the previously
identified mutations. The potential additional mutations are G15S and C18Y and they
both result in increased RAC1 expression levels [9].
Synonymous mutations as driver mutations
The genetic code uses 61 different codon triplets to encode 20 amino acids. This means
that there is overlap between codons and the amino acids they encode. Mutations that
change a nucleotide but do not result in a change in the amino acid are known as syn-
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onymous mutations. These synonymous mutations can however influence the messenger
RNA (mRNA) translation accuracy and speed, mRNA folding, mRNA splicing, or through
translational pausing how the protein folds. As such while the mutation may be silent in
respect to the amino acid it may have other effects on the function of the sequence and
the protein. Synonymous mutations thus may play a part in cancer formation [50]. Syn-
onymous mutations are the second most frequent type of point mutation after missense
mutations, and they have been studied less than missense mutations in cancer [46]. Driver
mutations have often been distinguished from passengers by comparing the frequency of
protein-coding changes to the frequency of synonymous mutations within genes. This
approach is obviously not suitable for detecting synonymous mutations which are under
positive selection.[50].
A pan cancer analysis of synonymous mutations found that the fraction of recurrent syn-
onymous mutations, 26.8%, was similar to the fraction of recurrent missense mutations.
The most frequent synonymous mutation was NCOA6 c.807G>A which was found 63
times. The most frequent synonymous mutation that has not been listed as polymorphism
was found 45 times. The mutation in question was CHEK2 c.1176G>T, it is located in a
tumour suppressor gene. The genes TTN and KCNJ12 both had multiple occurrences of
synonymous mutations. For TTN this is likely explained by its length [46].
Oncogenes that are known to be activated by missense mutations are also enriched by syn-
onymous mutations. These oncogenes have 23% to 30% excess of synonymous mutations
in their exons compared to genes with similar genomic features. This same phenomenon
is not seen in tumour suppressor genes and instead they may have less than expected
synonymous mutations in their exons. Synonymous mutations are also enriched in the
whole genomes and not just in the exons. Variation within the local mutation rate is
thus unlikely to explain the enrichment of synonymous mutations. This enrichment is also
not seen in oncogenes that are amplification or translocation activated [50]. Synonymous
mutations are also enriched within known cancer genes [46].
The enrichment of synonymous mutations cannot be explained by these mutations hitch-
hiking on positively selected missense mutations in missense-activated oncogenes. Onco-
genes with missense mutations are unlikely to contain synonymous mutations in the same
gene within the same tumour sample. The avoidance of missense and synonymous mu-
tations in the same gene are strongest in oncogenes mutated within a particular tissue.
This avoidance is not seen in tumour suppressor genes. Some cancer types are more likely
to have synonymous mutation enrichment and others have lower enrichment. The enrich-
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ment is generally lower in cancer types with a high mutational load such as melanoma
or head and neck cancers. Cancers that have low mutational load such as leukaemia and
breast and ovarian cancer have more synonymous mutation enrichment. Within individ-
ual tissues the synonymous mutations and missense mutations are enriched in the same
tissue-specific oncogenes. These mutations however are not seen together in the same gene
within the same sample [50].
Analysis of a group of receptor tyrosine kinases, IL7R and TSHR receptors, the structural
protein ELN, cytoplasmic kinases JAK3 and ITK and the transcription factors GATA1
and RUNX1T1 and a few other genes showed that synonymous mutations target evo-
lutionarily conserved synonymous sites. Within these genes the synonymous mutations
are likely to appear within five codons of another synonymous mutations creating clusters.
This is similar to the phenomenon of missense mutation clustering in oncogenes [50]. Both
missense and synonymous mutations are generally depleted near the 5’ and 3’ ends of the
exons. At 5’ end the strongest depletion is seen within the first 10% of the coding sequence
but the effect is still seen within the first 50 codons. Similar pattern is seen in first, last,
and monoexonic transcripts. Within internal exons synonymous mutations are depleted
near intron and exon boundaries [46].
While conserved sites are targets of synonymous mutations, they do not seem to influence
oncogene activity by changing codon optimality, mRNA folding or by targeting micro
RNA (miRNA) binding sites. Instead, they seem to be enriched near exon boundaries and
preferentially result in the gain of exonic splicing enhancer or the loss of exonic splicing
silencer. This phenomenon is stronger in sites where the flanking splice site sequences
diverge much from the consensus sequence resulting in weaker splice sites. Oncogenes with
synonymous mutations were associated with abnormal splicing compared to oncogenes
with non-synonymous mutations or non-cancer cells with synonymous mutations [50]. In
a pan cancer analysis 26.8% of synonymous mutations caused a change in predicted exonic
splicing enhancer or the loss of exonic splicing silencer. More than 40% of synonymous
mutations seem to target conserved sites. Synonymous mutations aside from affecting
splicing can also affect alternative promoter usage. Alternative events associated with
synonymous mutations are mostly exons known to be subject to alternative splicing [46].
Synonymous mutations are similar to missense mutations in their nucleotide changes.
Common nucleotide changes are C→T and G→A substitutions. While missense and
synonymous mutations were similar in nucleotide changes, they were different on amino
acid level. Synonymous mutations were enriched in hydrophobic amino acids. For example,
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synonymous mutations were enriched in phenylalanine codons. When assessing structural
impact on mRNA, transversions involving G had the largest structural impact. C→T
transitions on the other hand had smallest impact [46].
So far synonymous mutations have been mostly associated in changes within alternative
splicing. Structural changes caused by synonymous mutations in mRNA could affect its
stability, translation efficiency, and folding. Stable mRNA pseudoknot structures cause
translational pausing and regulate translation speed. This impacts co-translational protein
folding and the interactions with cellular components. The first codons of mRNA are
generally depleted of synonymous mutations. The mutations that are present within the
first codons are likely to have stronger structural impact [46].
KRAS belongs to a family of oncogenes called RAS and they encode small GTPases.
Mutations in RAS genes can lead to inhibition of GTP hydrolysis. Mutations in RAS are
quite common in human tumours as 30% of them have a RAS mutation. As such KRAS
is a commonly mutated oncogene. KRAS c.30A>C mutation is found near the 5’ end
of the sequence. This mutation affects the secondary structure of the resulting protein
locally. Synonymous mutations within KRAS codons 12 and 13 affect the expression rate
of KRAS with other mutations increasing it and others decreasing it. These synonymous
mutations could affect the oncogenicity of KRAS [46].
While tumour suppressor genes in general are not enriched in synonymous mutations.
TP53 however is an exception as it can be enriched for synonymous mutations. In TP53
the synonymous mutations target nucleotides directly adjacent to splice sites. Most of
these mutations are within the two terminal nucleotides of an exon. 3’ terminal nucleotide
synonymous mutation of TP53 ’s 4th exon is a recurrent target. In germline variant it
is known to cause Li-Fraumeni syndrome producing an aberrantly spliced mRNA. The
mutation causes intron retention and activation of cryptic splice sites. Another exon where
this happens is the 6th exon. In this exon a mutation can cause activation of a cryptic
splice site 5 nucleotides downstream from the end of the exon resulting in a frameshifted
mRNA. The terminal guanine is also often lost in exon 9 [50].
Latent and mini-driver mutations
The sequencing of tumour genomes has revealed few new driver genes that have been found
to be mutated at high frequencies and instead there are many genes that are mutated at
lower frequencies. Thus, it is possible that rather than there being few driver mutations
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with major impact on the fitness of cancer cells there are many mutations that provide
only small selective advantages to the cancer cells. These mutations that have only small
effects on the fitness of the tumour are called either mini-driver mutations [6] or latent-
driver mutations [35]. As such the mini-driver mutations do give an advantage to the
tumour cells but are not crucial for them. As the tumorigenesis progress the number of
mini-driver mutations would increase in the tumour cells [6]. While individual mini-driver
mutations will not confer a selective advantage there is some evidence so far that the
presence of mini-drivers will worsen outcomes of lung adenocarcinoma patients [4].
Individual mini-driver mutations are likely be only present in small proportion of tumours,
but tumours are likely to have multiple mini-driver mutations in them and sub-clones are
likely to have their own mini-driver mutations that are not necessarily present in all cells
of the tumour. As the mini-driver mutations have only a small effect it would be unlikely
for all sub-clones to have the same ones. Sub-clones could have convergent evolution
between their mini-drive mutations too and while the mini-driver mutations might not
give an advantage to the tumour, they could give a competitive edge to a specific sub-
clone against the other sub-clones within the tumour. The opposite could also be possible
where some sub-clone has mini-driver mutations in it that are deleterious. The targets of
mini-driver mutations would likely include non-coding genomic features such as regulatory
elements, transcript switching, and RNA stability [6].
Multiple mini-driver mutations could also substitute for a more major driver. In this case
their effects would likely be weaker than that of the major driver. Most mutations in
KRAS in cancer are found from its codons 12 and 13 with occasional ones found from
codon 61, however codons 146 and 117 can have atypical clonal mutations in them. It is
possible that these atypical mutations could act as mini-driver mutations [6].
Mini-driver mutations could also potentially adjust the effects of mutations that are al-
ready present in the tumour. Such adjustments could be for example, that the mini-driver
mutation amplifies the effects of a major driver or that it compensates for deleterious
mutations that the tumour has accumulated already. These adjustments could happen to
major drivers too, because the major driver may have affected the tumour growth posi-
tively before but as the environment and mutations in the tumour have changed this may
no longer be so. Mini-driver mutations could also remove functions in the cancer cell that
it no longer needs. Passenger mutations could also change into mini-driver mutations as
the tumorigenesis progresses further [6].
Alternatively, these types of mini or latent drivers could work so that all additional latent
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drivers have a small effect individually, but their cumulative effects start to cause changes.
It is also possible that individual latent drivers do not have an effect and instead two or
more mutations are needed for any change. In this case if two mutations are needed then
having either mutation alone would leave them as passenger mutations. Regular driver
mutations by contrast would have an effect even if they were present alone [35].
Cancer symptoms usually take a long time to emerge compared to drug resistance which
may emerge quickly within cancer. The reason for this may be these latent driver mu-
tations. Most research considers driver and passenger mutation distinction to be binary.
However, under some conditions a passenger mutation could act as a driver instead. In
drug resistance it may be that the mutations already exist as passengers in the tumour and
the change in selective pressure changes them into driver mutations leading to the growth
of the tumour [35]. There is so far some evidence that the accumulation of mini-drivers
within genes, that are part of extracellular matrix organisation, epithelial-mesenchymal
transitions, and blood vessel development and circulation in lung adenocarcinoma leads
to worse survival of patients with this disease [4].
Identifying mini-driver mutations is a challenge as they are likely to be uncommon across
cancer types and they may only be present in sub-clones and be present in cancers with
high background mutation rates [6]. Conventional methods that are used for identifying
driver mutations tend to focus on mutations that have a significant effect on the target
gene or protein or ones that have a significantly higher recurrence that would be expected.
These models are unlikely to work on mini-driver mutations as they do not have significant
effects on their targets alone. Analysis of larger modules that accumulate mutations
however seems promising [4].
Non-Coding driver mutations
Non-coding driver mutations have been less studied in comparison to coding mutations
[53]. One reason for the smaller focus on non-coding regions is that it has been difficult
to annotate the variants found from the non-coding regions [23]. An estimated 98% to
99% of the human genome is non-coding [1]. The non-coding regions contains multiple in-
teresting regulatory elements such as promoters, enhancers, and insulators which regulate
gene expression within the non-coding regions that could be targets of driver mutations.
Promoters bind core transcriptional complex to itself while enhancers bind transcription
factors, which can affect gene expression rates greatly. [40] Driver mutation identification
is more difficult in non-coding regions due to poorer understanding of the mutational pro-
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cesses there. Another challenge is in building a background mutation model which can
be difficult due to lack of easily interpreted neutral events the mutations could be com-
pared to [43]. In a pan-cancer analysis of somatic mutations a fourth of tumours had at
least one potential non-coding driver mutation. The most well characterised non-coding
region affected by driver mutations is the TERT promoter and it was affected in 9% of
the tumours. TERT is a gene responsible for maintaining telomere length. According
to the same analysis individual enhancers and promoters are infrequent targets for driver
mutations [53].
Over expression of TERT can be caused by point mutations that lead to the formation of
a new transcription factor binding site, insertions of viral enhancers upstream of the gene,
or through chromosomal amplification [53]. In TERT promoters non-coding mutations
can cause new binding sites for the ETS family of transcription factors. This leads to
over expression of TERT and subsequently increased telomere length maintenance and
cell survival [40] [36]. TP53 may occasionally be affected by non-coding mutations. SNVs
and deletions in its promoter can affect the transcription start site or donor splice site
of the first intron. These mutations often occur with loss of heterozygosity and result in
lower mRNA expression. This type of inactivation of TP53 by non-coding mutations is
still infrequent in tumours [43].
Amplification activated oncogenes show enrichment of mutations in the 3’ untranslated
region (UTR). This enrichment in 3’ UTR is generally seen in cancer genes that have
elevated expression levels in the tumour [50]. Mutations in the 3’ UTR of different genes
can cause either the expression of the gene to decrease, as happens with TOB1, or to in-
crease, as happens to NFKBIZ. TOB1 encodes an anti-proliferation regulator and affects
migration and invasion in gastric cancers. NFKBIZ 3’ UTR mutations concentrate in a
hotspot near the stop codon and upstream of conserved miRNA binding sites [43]. Recur-
rent mutations in 3’ UTR of NOTCH1 result in aberrant splicing in chronic lymphocytic
leukaemia. 3’ UTR mutations of CD274 on the other hand in gastric cancer patients have
been shown to disrupt miRNA mediated degradation of mRNA resulting in overexpression
[36]. Mutations in the promoter or 5’ UTR of MTG2, have been associated with lower
expression of MTG2 and the effect of these mutations has previously been studied in vitro
showing similar results [43].
Non-coding mutations in haematological malignancies have been identified to be active
in the pre-transcription regulation of genes. Enhancer activity is often targeted towards
a specific promoter by containing the enhancer-promoter loop with insulator elements.
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These insulator elements anchored by CCCTC-binding factors known as CTCFs. Mu-
tations in the CTCF elements, hypermethylation of CTCF binding motifs, or mutations
in the cohesin complex can result in loss of insulation. This then can result in aberrant
gene expression of the neighbouring genes [40]. One of the genes associated with CTCF
mutations is TGFB and it promotes blood vessel formation and tumour cell migration
in melanoma [22]. Different tumour types have different pattern of mutation in cohesin-
binding sites. Pol ε exo− tumours have a reduced rate of somatic mutations near the
site while microsatellite stable (MSS) tumours tend to have a spike of mutations at 17-bp
CTCF binding motif. MSI samples have a somewhat lower mutation frequency overall
near the cohesin-binding sites [15].
In blood cancers there are mutations within the non-coding genome that lead to aber-
rant regulation of gene expression. These kinds of mutations are present in T-cell acute
lymphoblastic leukaemia. Such mutations are for example present in TAL and LMO tran-
scription factors. The mutations cause these genes to be dysregulated. These transcription
factors are expressed in early T-cell differentiation and mutations, in the aforementioned
genes, result in T-cell differentiation disruption and the proliferation of malignant precur-
sors. The mutations do not always have to be present within the transcription factor gene
or binding site and instead they can be found from elsewhere in the genome. In the case
of TAL1 it can be influenced by a non-coding mutation 7kb upstream. Indels of length
2 to 18 bp at this location can cause transcription factor MYB to bind at this location.
MYB is a master transcription factor and it is capable of recruiting TAL-LMO complex
at this aberrant site resulting in expression of TAL1 from this location [40].
Medulloblastoma is a highly malignant paediatric brain tumour, and it can be classified
into four subgroups. Subgroups 3 and 4 are the mostly poorly understood ones and
GFI1 and GFI1B are highly prevalent oncogenes in these groups. Structural variants at
9q34 cause upregulation of GFI1B by moving it under the regulation of super enhancers.
As with GFI1B the activation of GFI1 is also often associated with structural variants.
GFI1 is also associated with enhancers as it can translocate to highly expressed sites.
Both GFI1B and GFI1 activate when they end up near enhancers and they can work
together with MYC to induce cancer. This type of enhancer hijacking may be present in
other oncogenes too [34].
Non-coding RNAs may also play a part in cancer. The non-coding RNA RMPR can
have significantly mutated exon and promoter in multiple tumour types. These mutations
tended to accumulate in sites that can affect the secondary structure of proteins [43]. There
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are several different RNAs and possible modifications in the non-coding genome such as:
mRNA splice sites, non-coding RNA genes, and long non-coding RNA (lncRNA). The
last ones are especially interesting as lncRNAs can control gene expression. For example,
HOTAIR lncRNA is highly expressed in breast tumours and metastases and [21] lncRNA
MALAT1 has been shown to be mutated in oestrogen receptor positive breast cancers
[36]. mRNA expression can also be altered by mutations in if the mutation happens in
miRNA that regulates mRNA or in the mRNA where the miRNA is supposed to bind to.
[21].
2.5 Detecting driver mutations and genes
Driver genes and driver mutations have both been looked for by multiple different algo-
rithms, but they tend to follow similar principles for the most part [39] [29]. The algo-
rithms can either focus on gene level detection of driver genes or sub-gene level and look
for individual driver mutations or clusters of driver mutations. Both levels of algorithms
can focus on detecting driver elements from either linear sequence, usually either DNA or
amino acid sequences, or they focus on detection from 3D structures of proteins [39] [29].
Most algorithms in driver detection work by comparing the background mutation rate
and the expected distribution of mutations or the expected types of mutations against the
observed mutations. A challenging aspect within these methods is that the background
mutation rate is different between different cancer types and even between different in-
dividuals. Thus, building a model that can accurately model the background rate well
is critical [29]. Most tumours can also have thousands of mutations and usually these
mutations are unique to that tumour and other tumours are unlikely to share them. This
is explained by the driver-passenger division of mutations, where most of the mutations
are passenger mutations that are rarely seen across different tumours. In this view the
rare but recurrent mutations are likely to be driver mutations while the more common but
not recurrent mutations are passengers [39].
On the gene level driver genes can be detected by detecting positive signals of selection
for the gene in the cancer. First, the number of observed mutations can be compared to
the number of expected mutations. Secondly the mutational clusters present can signify
positive selection as there can be clusters either in domains of interest in the linear sequence
or there may be clusters in the protein 3D structure, which in the linear sequence may
be far away from each other. Normally in the case that there is no positive selection the
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expected distribution of these mutations would be more random. Instead of clusters it is
also possible to see biases in the mutations in some way. For example, the mutations in a
gene may have higher than expected number of mutations with high functional impacts.
There could also be bias in the nucleotide context of the mutations in that some nucleotide
contexts accumulate more mutations than expected [29].
The sub-gene level has similar algorithms to the gene level. The sub-gene level algorithms
also mostly focus on finding clusters from either linear sequences or 3D structures. These
sub-gene algorithms can be classified into four subgroups. The first group consists of
algorithms that look for clusters of mutations in the sequence. The main differences
between methods in this class is the background model they use. The second group consists
of methods that look for the mutational clusters from 3D structures of the proteins. The
exact way these methods work can vary in how they interpret the 3D data they use. The
third group is like the first one in that these methods also look for linear sequences but
the sequences in this case must have known functional regions. In this group the methods
compare how large portion of the mutations are within the functional region compared to
the rest of the sequence. The third group also has methods that analyse the same domain
in multiple different proteins to find recurrently mutated positions. The fourth group is
like the second and third and the methods in this group look for externally defined regions
in the 3D structures of proteins [39].
The algorithms that rely on 3D protein structures and externally defined interesting do-
mains have their limitations in practical use. Experimentally determined protein struc-
tures are available for only a limited number of proteins. Similarly, the need for domains
limits the studied sequences to those for which there is knowledge on the functional do-
mains in the sequence [39].
On the sub-gene level algorithms that belong to the same group tend to get similar results.
Overall, sub-gene algorithms are more likely to find oncogenes than tumour suppressor
genes. This could be because these algorithms tend to focus on finding clusters of muta-
tions within genes, and oncogenes potentially have more mutational clusters than tumour
suppressor genes, while gene level methods focus more on mutational recurrence of a gene
in a cohort [39]. Different sub-gene and gene level algorithms can be used together to com-
plement each other and to ensure that they look at variety of features of the mutational
pattern in genes. This ensures that a wider variety of driver genes are found [39] [29].
While many algorithms can be classified in the above-mentioned categories, in the principle
on which they operate on when detecting signals of positive selection of mutations in genes,
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there are many other algorithms that work differently. For example, deep learning can be
used to detect driver mutations based only on the raw sequence data. Deep learning allows
the model to learn independently the important features from the input data. This means
that the model focusing on detecting driver mutations from pure DNA sequences should
learn the features that separate driver mutations from sequences that do not contain driver
mutations [2]. Deep learning is further discussed after the different ways of detecting and
scoring mutations.
Introduction to previously used driver mutation and gene finding frameworks
One algorithm that belongs to the sub-gene algorithm category 1 algorithms is Onco-
driveCLUST [39]. OncodriveCLUST uses clusters of mutations within specific regions of
amino acid sequence to detect driver mutations. It compares the measured bias of mutation
clustering compared to its background model, which consists of coding region synonymous
mutations. As the synonymous mutations are assumed to not be under selective pressure,
they should reflect the baseline of somatic mutation clustering. OncodriveCLUST consists
of five steps where it retrieves all non-synonymous mutations and positions, the ones that
have mutation frequency above the background threshold rate are identified as cluster
seeds. After this these cluster seeds are joined together to form a cluster if they are close
enough to each other and mutations which fall into these clusters are added to them if
they were not identified as cluster seeds. Lastly, a score is calculated for the cluster, the
score is directly proportional to the fraction of mutations within the cluster and inversely
proportional to the cluster length. The final score for a gene is calculated by summing
over all clusters in it. OncodriveCLUST is better at finding recurrently mutated drivers
and less likely to work well for tumour suppressor genes as they may have more even
distribution of mutations [51].
LARVA is a computational framework designed to find highly mutated regions in the
genome and especially in the non-coding regions of the genome and regulatory elements.
LARVA treats the mutation count in the given regulatory regions as beta-binomial dis-
tributed random variable. LARVA’s workflow starts by pre-processing mutations through
quality control and intersecting them with annotations for regulatory regions in the non-
coding regions. The processing itself consists of counting all variant intersections with the
annotation categories and corrected for covariates. Significance analysis is then performed
by fitting a background model, beta-binomial distribution, and then p-values are calcu-
lated for the regions under analysis. LARVA is for example capable of detecting that the
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TERT promoter is a significant region [23].
deepDriver is a framework that can predict driver genes based on somatic mutations using
convolutional neural network architecture. deepDriver uses a similarity network between
mutations as its input. The similarity network is constructed by calculating Pearson’s cor-
relation coefficient between 12-feature vectors constructed for genes. The feature vector,
for example, contains the fractions of different mutation types. The similarity network is
then constructed by calculating correlation coefficients between the genes and connecting
them to each other. A gene is connected to k other genes with the k highest correlation
coefficient values by k-nearest neighbours’ algorithm. The similarity network is then rep-
resented as a matrix that is used as the input in a convolutional neural network consisting
of two convolutional layers and a fully connected layer [24].
Convolutional neural networks can also be used to detect driver mutations from the DNA
sequence alone. Training a convolutional neural network to detect driver mutations will
also need sequences which do not contain driver mutations as the negative examples. The
convolutional neural network should directly learn the important features for separating
sequences with a driver mutation from sequences with no driver mutations. The length of
the sequence is also important as too long sequences may contain unimportant information
that may end up confusing the neural network. Methods like this are still somewhat limited
as the linear DNA sequence does not capture potential three dimensional effects that may
contribute to the mutation processes [2].
Mut2Vec is a pipeline that generates distributed representations of mutations and it can
separate passenger and driver mutations from each other. In this case if an unidentified
mutation is close to many known driver mutations in the distributed space, then it too is
likely a driver mutation. Mut2Vec is based on Skip-Gram model. The Skip-Gram model
is a multi-layered neural network. It consists of an input layer, an embedding lookup layer
and the prediction layer. Its goal is to predict surrounding entities based on the entity
embedded within the network. This is achieved by training the model on an entity and
its surrounding contextual entities. In the case of Mut2Vec the Skip-Gram is first trained
on PuBMed abstracts to extract the context of genes and the lookup layer is initialised
with gene word vectors. After this the model is trained with gene-level mutation vectors.
Lastly, the model can be retrofitted with protein-protein interaction network data from
BioGRID. This results in gene-level mutation vectors. These vectors can then be used
to represent mutations in a two-dimensional space and passenger mutations and driver
mutations end to cluster to their own groups [17].
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ParsSNP is a parsimony based unsupervised method for prioritising driver mutations.
ParsSNP assumes that the proportion of driver mutation drops as the number of mutations
in a sample increase. ParsSNP uses an expectation-maximisation framework. In the
training phase ParsSNP assign a random label between 0 and 1 for each variant and
calculates descriptors for the variants. The descriptors can be calculated or obtained from
other methods. During the expectation step the labels are updated using the Bayes Law
and the belief that in a sample with N mutations, between 1 and log2(N) mutations are
drivers. The maximisation step has a probabilistic model that updates the labels according
to the descriptors. The expectation and maximisation steps iterate until convergence is
achieved. The final labels are then used to train a separate neural network, which can then
take new input variants and score them. The final score correlates with the recurrence of
a mutation and the score can be used to indicate potential driver mutations [19].
OncodriveFML
OncodriveFML is one widely used framework for detecting coding and non-coding driver
mutations. The idea behind OncodriveFML is that tumours have a bias towards accumu-
lating high impact mutations in certain genomic regions [32].
OncodriveFML uses functional impact score (FI) and functional mutation score (FM).
Functional impact means that the score can for example measure the mutations effect on
the protein structure or the binding affinity of different molecules and their binding sites.
Functional impact can also measure effects on the mRNA. Functional impact score can
be any score of this type that can be calculated for all positions in the genomic elements
under analysis. For example, a score that can be used as FI score is the CADD score
[32, 42]. The only requirement for FI is that it is meaningful for the genomic elements in
question [32].
OncodriveFML starts by first gathering the FI scores for the observed mutations from a FI
score file provided for it. Then it calculates the average FI score for the observed somatic
mutations. After this OncodriveFML samples N times the same number of mutations
randomly from the FI score file and calculates the mean FI scores for these N instances.
The sampling of the mutations can be done by having the same probabilities for all mu-
tations or the mutation probabilities can be calculated from the observed mutations. It is
also possible to set custom probabilities. Thirdly OncodriveFML compares the observed
average FI score with the mean FI values from the N sampling instances. OncodriveFML
calculates an empirical p-value for the observed mean FI score by comparing it to the N
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mean FI values. This is done by calculating how many times the observed mean FI value
is bigger than the randomised mean FI value. This value is then normalised by dividing it
with the number of randomisations performed. Lastly, OncodriveFML performs multiple-
testing correction with Benjamini-Hochber correction to rule out false positives that may
have been generated during the N sampling procedure [32].
2.6 Scoring methods for functional impact and pathogenic-
ity of mutations
There have been multiple attempts to score mutations according to their functional impact
or by their pathogenicity. Below are some examples on what kind of scores have been made.
Cancer Mutation Census
Cancer Mutation Census (CMC) is a project that classifies the coding mutations in Cat-
alogue Of Somatic Mutations In Cancer (COSMIC) and attempts to find variants that
are driver mutations in cancer. CMC ranks the mutations into mutation significance tiers
based on the available evidence if the mutation is pathogenic or not. The tiers are 1,2,3
and ‘Other’. Tier 1 is the highest pathogenicity tier and mutations in this category are
classified as pathogenic. Mutations are classified into this category if they have clinical
significance 5 in Clinvar cancer-related diseases and it is a recurrent missense mutation in
oncogene or a loss-of-function mutation in a tumour suppressor gene. Significance level 2
mutations can be like category 1 mutations, but the clinical significance level is 4 instead
of 5. Alternatively level 2 mutations may have clinical significance level of 4 or 5, but it
is not recurrently present in known oncogenes or tumour suppressor genes, but still shows
evidence of positive selection by a dN/dS algorithm. Alternatively level 2 mutations may
be recurrently present in known cancer genes and show evidence for positive selection but
have no Clinvar evidence. Level 3 mutations show one category of evidence as they can
be either recurrently present in known oncogenes or tumours suppressor genes, or show
evidence of positive selection, or have Clinvar significance of 4 or 5. Mutations in the




Combined Annotation-Dependent Depletion (CADD) is a score that can be used to mea-
sure the deleteriousness of a variant. The scores are based on various features such as
sequence context, gene model annotations, evolutionary constraint, epigenetic features,
and functional predictions. CADD uses a machine learning model, such as logistic regres-
sion, to then predict a score for a variant based on these features [42]. For training CADD
uses alleles that have fixed since human-chimpanzee lineages diverged as likely benign or
neutral variants as otherwise we might expect them to have disappeared if they were very
deleterious. Another group of variants CADD uses in training are a group of simulated
mutations that are free of selective pressures. Most of these simulated mutations are also
likely benign but a group of deleterious mutations should also arise from them. The dif-
ference in their annotation features is used in making the final score when training the
machine learning model [42]. A limitation of CADD is that some of the simulated variants
are neutral but it is unknown which. Because of this CADD’s performance is evaluated
on known curated datasets of different diseases or functional effects [42].
CADD score can also be divided into the RAW and PHRED scores. The RAW score is
the raw output from the model, and they are not comparable between training rounds or
different models. High RAW score means that the variant has been more likely derived
from the simulated variant dataset rather than the neutral variant dataset. This means
that higher RAW score indicates higher deleteriousness. PHRED scores are scaled so
that the score indicates in which percentile it is. This means that PHRED scores can be
compared between each other as regardless of the details in the model a score of 20 or
greater would indicate that the score is in the top 1% of scores [42].
Synonymous Mutations In Cancer database
Synonymous Mutations In Cancer database (SynMICdb) is a score that was created for
659,194 synonymous mutations from 13,935 tumour samples to measure the functional im-
pact of synonymous mutations. The synonymous mutations were curated from COSMIC
v76. This score consists of mutation frequency, mutational signature, mutation load, evo-
lutionary conservation, cancer gene annotation, SNP annotation, FATHMM-MKL score,
CADD score, and predicted RNA secondary structure changes. The frequency indicates
the frequency of the mutation after correcting for mutational bias. The mutational load
indicates the mutational load of samples affected by the mutation. The SynMICdb score
30
ranges from -4 to +12, with higher score indicating a higher likelihood of the mutation
having a functional impact. A score higher than 0.89 would put the mutation into the top
50% while a score of 4.38 puts it in the top 1% [46].
Oncogenic driver Variants
Oncogenic driver Variants (OncoVar) is a platform for driver genes and driver mutations.
The cancer data is gathered from the TCGA data and International Cancer Genome
Consortium (ICGC). The platform has cancer type and dataset specific files for download.
The interesting features of the OncoVar platform are the OncoVar scores for mutations and
genes, the consensus-score and driver level. The OncoVar scores measure the ’driverness’
of a mutation or a gene. Driver mutations were defined as mutations that had high scores
and occurred in at least two samples. Driver genes were based on a consensus score from
multiple other driver gene sets, including Cancer Gene Census, and if it had high enough
score it was assigned as a driver. OncoVar scores were adjusted also on a Gaussian model
so that they could be compared. A higher OncoVar score indicates higher pathogenicity.
[52].
2.7 Deep Learning
Machine learning methods attempt to learn relationships between features from the data
without having to predefine what they might be beforehand [3]. Deep learning is a subfield
of machine learning where the methods are representation learning based. Representation
learning allows for the automatic discovery of features from raw data without human
interference. This contrasts with classical machine learning methods where features had
to be carefully engineered by domain experts. This however did not always yield very
good results hence deep learning techniques were developed to deal with these issues
[20]. The representations in deep learning methods are multi-layered where each level
of representation is obtained by composing non-linear functions on the representation
from the previous layer. With enough layers very complicated features can be learned.
The higher-level layers will learn which features are important for discriminating different
classes from each other and which ones are irrelevant in classification tasks. Deep learning
methods for example may learn from image data edges and what kind of patterns and
shapes these edges form [20].
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A common type of deep learning model is the deep neural network. The architecture of
a deep neural network consists of an input layer, hidden layers, and an output layer. The
input layer simply takes the input and moves it to the next hidden layer. Hidden layers in
neural networks consist of neurons that get an input from the previous layer [3], multiplies
it by the weight of the neuron and passes it on through an activation function to the next
layer. If the neurons of one layer are all connected to all neurons from the next layer, then
the layer is called fully connected layer [20]. In the case the neurons are only connected
to a few neurons in the next layer the layer is called a convolutional layer. Convolutional
layers consist of filters, a set of weights, that are moved over the input and they pick up
features from the data. The result is that in the next layer there are smaller inputs that
the filters from the previous layers created. The convolution is generally followed by the
activation function that decide if the neuron is going to be activated or not [3]. A common
activation function is called ReLU, rectified linear unit, its function is max(0, z) [20] and
if the value of the neuron is below or at zero the neuron will not fire [3].
Convolution is generally followed by a pooling layer in convolutional neural networks.
The purpose of a pooling layer is to reduce the dimensionality of the feature maps from
the convolutional layers by merging similar information from close by points. A common
method of pooling is called max-pooling, where the maximum values from local regions
are passed onto the next layer [3]. Pooling layers are generally followed by another con-
volutional layer, which in turn is followed by another pooling layer. The combination of
convolutional and pooling layers allows the model to learn features from the data [20].
The feature learning stage is generally followed by classification. The output has usually a
SoftMax activation function. SoftMax transforms the output so that every possible output
category has a value between 0 and 1 and all output values sum up to 1 [11].
These types of neural networks are generally used for supervised learning and classification
tasks. In supervised learning the model is trained on data pairs that consists of the input
features and a target value. For example, an image of a dog would be the input and
the word ‘dog’ the target value. The point of supervised learning is for the model to
learn to minimise the difference between the real target values and the ones it predicts for
the input. The function it needs to minimise for this task is called the objective or loss
function. During the training of the model the weights of the neurons are updated after
each training round when the difference between the real and predicted values are known.
After training the model is done, the model can be used to predict the target values of new
data [20]. To speed up the training the data can be batch normalised before the activation
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function. This zero centres and normalises the data allowing higher learning rates during
the training [3].
In addition to supervised learning there is unsupervised learning where the target values
are not used. In this case the aim is to discover patterns from the data. Various clustering
methods belong to this class of learning [3].
3 Materials and Methods
3.1 Deep Mutation Modelling
Deep Mutation Modelling (DMM) is a method for modelling the probabilities of specific
types of mutations at a given locus in a DNA sequence. It uses a deep neural network
architecture to achieve this. The types of mutations DMM can model are single nucleotide
variants, multi nucleotide variants, indels, structural variants and mobile elements. It also
considers the possibility of there being no mutation at the given locus. DMM can also
learn the mutational probabilities given the tumour type and sequence context. This gives
DMM the potential advantage of giving cancer or even sample specific probabilities for
mutations at given sites. These could then be used to form cancer and sample specific
scores that can be used in further analysis. The input for the DMM model consists of
mutations with associated site and sample level features. DMM has three main modules
it consists of: the mutation event site, sample, and integrative site. Figure 3.1 shows the
modules and how they connect to each other [8].
Figure 3.1: DMM - a deep neural network model architecture to predict somatic mutation events,
Pitkänen et al. unpublished
The site module deals with the sequence input and site features, such as genic orientation,
replication timing or whether the site is in an exon or non-coding region, in a convolutional
neural network to learn these features and to predict the likelihood of mutational outcomes.
The input sequences are one-hot encoded as binary matrices. The site module in the end
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concatenates the sequence features extracted by the convolutional layers and processes
them and the site features with fully connected layers. The output of this module is a
feature vector. This module thus learns the sequence context of the mutations. [8]
The sample module processes sample related information such as such as tumour type,
patient age and sex, sequence coverage etc. These features are processed by one-hot
encoding the categorical inputs. They can then be given as input to another fully connected
layer in the sample module which will output a sample level feature vector. The sample
level output is the same for all input mutations that are from the same sample [8].
The third module is the integrative module which uses the feature vectors from the two
previous modules as its input and processes them with fully connected layers. The layers
use ReLU as the activation function except in the last layer where SoftMax is used instead.
The output from this module is, given a mutation alphabet the size of m, a matrix of
shape (c x m), where c is the length of the sequence around the central mutation that is
considered. The rows in the output matrix represent the nucleotides and the columns the
possible mutational outcomes [8].
The loss function DMM attempts to minimise is L = H(Y, Ŷ ) + λ‖zs‖1, λ > 0 where
zs is the feature vector from the sample module. H is the cross entropy of the real and
predicted mutations [8].
Overall, the model learns the probability of the mutational outcomes given the sequence
context and sample representation. As driver mutations are expected to occur in more
unusual mutational contexts, they are expected to be more difficult to predict with DMM
than passenger mutations and thus should have lower accuracy for the true mutation
prediction and lower probability of predicting any mutation [8].
DMM is trained by giving it sequences that contain a mutation in the sequence centre
position. DMM is also given sequences where the centre position does not have a mutation
as negative examples. The negative examples are generated by drawing a set of mutations
for each sample from any other sample s 6= ŝ. These random mutations would then be
represented by a mutation string with no mutation and the sample being s. In short,
the negative examples are real mutation in some other sample but are represented as
being an event with no mutation in the original sample s. Based on these examples like
other neural networks DMM should learn the features from the sequence that affect the
mutation probability alongside with the sequence features. DMM also has the capacity
to learn which samples have high number of mutations and which have lower number of
mutations. Figure 3.2 shows what kind of sequences DMM can take as its input [8].
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Figure 3.2: DMM input and output examples, in subfigure A the first sequence contains a C→T mutation
represented by a wedge in the middle of the sequence, while the second sequence has the same mutation
and an additional C→A represented by $ symbol in it. DMM uses the central mutation as its input.
In subfigure B the output of DMM is originally a matrix which has probabilities for different predicted
mutations for the central mutation. The matrix can be changed into a mutation vector that has the
same probabilities. Additionally, it has probabilities for any mutation, the true mutation, and the highest
predicted value.
The mutational outcome is given so that each mutation has a predicted probability for
every possible mutation type as seen in Figure 3.2. Additionally, the probabilities for any
mutation to have happened (pany), the probability of the true mutation to have happened
(ptrue), and the probability of the mutation type that has the highest probability (ppred)
[8].
3.2 Materials
TCGA and PCAWG datasets
The main data I used were the Pan Cancer Analysis of Whole Genomes (PCAWG) [53]
and The Cancer Genome Atlas (TCGA) datasets. The PCAWG dataset consists of whole
genome sequence data from tumours while the TCGA is only based on exome sequence
data from tumours. Both datasets used GRCh37 genome assembly.
The datasets had been annotated by DMM previously so that the data consisted of the
mutations, associated sequence, and a few sequence features such as replication timing.
Mutations that had no sample ID in associated sample information files were dropped.
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The PCAWG DNA sequences I used, were 2048 base pairs long and the TCGA sequences
were 256 base pairs long. I limited my analysis only to single nucleotide substitutions. In
both cases I only examined mutations that, according to DMM’s annotation process, were
within exonic and genic regions, had a known replication timing, and were not duplicates
of each other in the same sample. I also noticed some mutations within the TCGA dataset
that had no known cancer type or sex of the patient associated with them and I dropped
these from the analysis. The TCGA dataset also contained mutations that had reference
or alternative allele sequence longer than one base pair, these mutations were also dropped.
In the end I had 739,341 mutations in the PCAWG dataset and 2,547,192 mutations in
the TCGA dataset that I used for further analysis. The substitution counts can be seen
in Table 4.1. According to this table C→T : G→A substitutions were the most common
ones. These mutations covered 2636 different tumour samples in the PCAWG dataset
and 8941 samples in the TCGA dataset. Figure 3.4a shows the number of samples and
mutations per cancer type in the PCAWG dataset while 3.4b shows the number of samples
and mutations in the TCGA dataset.
Both datasets had more samples from males than females. The male samples outnumbered
female samples by 275 in the TCGA dataset and by 268 in the PCAWG dataset. The
number of male and female samples and the mutations in them are shown in Figure 3.3.
There were more samples from individuals of European backgrounds than from other
ethnicities. In the TCGA dataset I had 6545 samples classified as white and in PCAWG
dataset there were 1945 samples classified as European.
(a) PCAWG mutations (b) TCGA mutations




Figure 3.4: Number of mutations in different cancer types in the PCAWG and TCGA datasets
Functional impact and pathogenicity scores
I also used other data and scores meant for analysing the pathogenicity of mutations. The
scores I used were SynMICdb, a score for the functional impact of synonymous mutations
[46], CADD v. 1.6 is a score for the predicted deleteriousness of mutations [41], Cancer
Mutation Census (CMC) contains classification of mutations into different classes based on
their pathogenicity [47] and I used CMC data v92 for my analysis, and OncoVar is also a
score for the pathogenicity of mutations [52]. OncoVar has data based on different cancer
types and datasets, I used pan-cancer TCGA data for my analysis from the OncoVar
database. Additionally, I used Ensembl Variant Effect Predictor (VEP) v.100 to annotate
the PCAWG and TCGA datasets with the basic options and with CADD v. 1.6. [31].
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I used SynMICdb with CMC mutations and first combined the CMC mutations with the
PCAWG and TCGA datasets based on genomic position and reference and alternative
alleles and then combined the SynMICdb based on the mutation ID available for both
CMC and SynMICdb mutations. I compared the SynMICdb score to the DMM pany and
ptrue by calculating the Spearman correlation between them and by making a scatterplot
between the different scores. PCAWG had a total of 22323 synonymous mutations for
which the SynMICdb score was available and for TCGA there were 114063 synonymous
mutations for which SynMICdb score was available. Similarly, to CMC I merged the
OncoVar mutations with my PCAWG and TCGA datasets based on the mutation position
and alleles for the mutation data and based on the gene for the gene level data. The
SynMICdb data is available for download at http://synmicdb.dkfz.de
I downloaded a cancer hotspot v2 mutation dataset from https://www.cancerhotspots.org.
The hotspots in this dataset were obtained from 24,592 cancer samples representing more
than 300 cancer types. The dataset contains 1165 significant hotspot mutations. 80% of
these mutations occurred in 1 in 1,000 or fewer samples [7]. The hotspots were in the
downloaded file grouped by codon. I separated the individual nucleotides from the codons
for my analysis. For each hotspot mutation I kept its location and reference and alternative
alleles. I used both positions only to merge the data to the PCAWG and TCGA datasets.
OncodriveFML input data
OncodriveFML [32] requires multiple different files for it to work. I used OncodriveFML
version 2.3. It requires a file with the input mutations, a region file that contains the regions
under analysis, and a score file that contains a score for every base within the region file.
Additionally, OncodriveFML requires a configuration file for running the program.
The real observed mutations were extracted from the curated PCAWG and TCGA datasets
mentioned earlier, by taking the mutations that were found from the skin-melanoma sam-
ples (PCAWG), MSI samples (PCAWG), and hepatocellular carcinoma samples (TCGA),
and skin cutaneous melanoma samples (TCGA) and written into cancer type specific files.
In total I had 107 skin-melanoma samples and 25 potential MSI samples from the PCAWG
dataset, 350 hepatocellular carcinomas and 468 skin cutaneous melanomas from TCGA.
In the case of the TCGA melanomas there were two more samples than in the mutation
dataset as these two did not have any mutations that fit the filtering categories and were
included by mistake. The genes I analysed were TP53, APC, KRAS, BRAF, ATR, TTN,
PCLO, BMPR2, GRIN2B, and SLC9A8. Out of these TP53, APC, KRAS, and BRAF
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are known cancer genes. The number of observed mutations per gene in the datasets is
shown in the Table 3.1.
Input mutations from the dataset into oncodriveFML
Gene/Dataset PCAWG Skin-
Melanoma




APC 17 22 13 51
ATR 9 12 13 52
BMPR2 17 13 4 19
BRAF 73 7 0 301
GRIN2B 207 40 4 191
KRAS 9 15 4 14
PCLO 238 35 58 723
SLC9A8 10 12 1 9
TP53 23 11 82 77
TTN 676 175 163 2945
Total: 1279 342 342 4382
Table 3.1: Input mutations for OncodriveFML
OncodriveFML also requires a region file which contains the gene regions to be included in
the analysis. The genomic locations for the test genes were obtained from BasePlayer [16]
genome browser using GRCh37-hg19 human genome assembly. The region file was made by
taking the genomic locations and removing the non-genic and non-exonic regions according
to DMM and the positions for which no replication timing was available. Positions which
were not genic or exonic were dropped as OncodriveFML does not recommend using coding
and non-coding regions together in the same analysis. The regions were then defined as
being the continuous position left. I also removed the continuous regions that according
to BasePlayer genome browser belonged to other genes or genomic elements. The region
file contains the chromosome of the continuous stretch of positions and the start and end
positions as well as the gene name and a segment number for the separate segments for
each gene.
A third important file for the function of OncodriveFML is the score file. Based on this, I
created a vcf file containing all reference alleles, from a GRCh37 reference genome, within
the regions and all three possible substitutions for each reference allele. Then the vcf
file containing fake mutations was annotated with DMM. The annotation adds known
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replication timing and information on if the position is genic and exonic for each position.
Annotation also adds the sequence surrounding the mutation, sequence length of 2048
was used for the PCAWG mutations while TCGA mutations got sequence length of 256.
Positions which were both genic and exonic and had a known replication timing were used
in further analysis. The files were then mapped with DMM to obtain the probability
outputs for all possible substitutions. Mapping was done individually for all combinations
of individual samples and individual genes. After mapping was done for each sample and
gene the probabilities for ptrue and pany were processed into score files. These files were
created for each four cancer types individually so that a −log10 was applied on every
probability. In the case where probability was zero it was replaced by the lowest non-zero
probability found in the mapped gene in the sample. After applying the logarithmic on
the probabilities, the modified probabilities were summed together and divided by the
number of samples to obtain an average score for the cancer type. Separate probability
files were made for ptrue and pany for all cancer types, the file for ptrue included the reference
alleles and the substitution specific probability score in addition to the chromosome and
position. The file for pany contained only the chromosome, position, and score for the
position without information regarding the substitution.
The configuration file contains the information for OncodriveFML on which signature
method to use and how to calculate the statistics. In this analysis the ’complement’
method was used, and statistics used arithmetic mean. The minimum number of sampling
was set to 100,000 while the maximum was one million. Minimum number of observations
was ten while sampling chunks was one hundred million. Multi nucleotide polymorphic
mutations were not included in the analysis. When running OncodriveFML the PCAWG
skin-melanoma and MSI datasets were given the whole genome setting while TCGA hep-
atocellular carcinoma and skin cutaneous melanoma were used with the whole exome
setting.
3.3 Methods
I first used DMM to map the PCAWG and TCGA sequences to generate mutation prob-
abilities for the mutations 739,341 mutations in the PCAWG dataset and 2,547,192 in
the TCGA dataset. The output consists of each mutation having a probability for each
mutation type provided by the DMM model used. I also used DMM to annotate the fake
substitutions needed to make the score file for OncodriveFML and the regions needed
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for the region file. Then I used DMM to map the fake substitutions to get mutation
probabilities for all of them.
For visualisation I used Uniform Manifold Approximation and Projection (UMAP) [30]. It
is a dimensionality reducing technique that can be used for visualisation and is especially
useful for non-linear reductions. UMAP works by finding a topological representation of a
lower dimension that is close to the original higher dimensional topological representation.
I used UMAP to reduce the dimensionality of the output from DMM to see how the muta-
tion probabilities and sample information cluster in two-dimensional space. I coloured the
mutation probabilities with various features to illustrate how the features are distributed
in the two-dimensional space.
I also calculated test statistics for different categories by doing Student’s T-test for in-
dependent samples to see if there were differences between the means of the different
categories. For correlations between different features and datasets I used Spearman’s
correlation coefficient, this way the distribution of the data does not need to be normally
distributed. Additionally, I used ordinary least squares regression to fit a linear model on
the mutation probabilities and sample features to examine how much of the variance in
the results can be explained by the sample features.
Most of the datasets I had I combined by using the chromosomal position and the reference
and alternative alleles to the PCAWG and TCGA datasets. In the case of CMC data and
the SynMICdb score I used a mutation ID that was available for both in place of the
mutation position and alleles. I used VEP to get the CADD score for all mutations.
The probability outputs from DMM can be used as scores in OncodriveFML. I tested the
probability scores pany and ptrue from DMM for the ten genes and compared them to the
CADD RAW and CADD PHRED scores. I used in OncodriveFML the files described in
the materials section.
4 Results
The first experiments I did with the data was to check how the substitutions I had in
the PCAWG and TCGA datasets fell into the six basic substitution categories. I was
also interested if there were differences between the substitution types on how many of
them were predicted correctly and incorrectly. Other question regarding these basic six
substitution types were how they were distributed in the two-dimensional space in relation
to each other so I used UMAP to reduce the dimensionality of the DMM probability output
vector so that I could visualise them. The visualisation is then based on the predicted
probabilities but coloured by the true mutation rather than the predicted ones. I also
used UMAP to reduce the dimensionality of the integrated layer vector, which contained
sample feature-based values, from DMM and coloured it the same colours as the probability
vectors. Additionally, I used boxplots to see if there is a difference between the predicted
probabilities for sequences which only contain the necessary input mutation within the
sequence and sequences that have at least one additional mutation somewhere in the
sequence.
The predicted probabilities from DMM are the most interesting output it has. I mostly
focused on the predicted probabilities for any mutation and for the true mutation. I
coloured the same UMAPs with these probabilities to see if the probabilities are clustered
in some areas of the image. I also calculated the mean probabilities for each sample and
compared them to the number of mutations in each sample to see how dependent the
DMM models are on the number of mutations when they predict the probabilities.
Since the integrated layer output also contains information not only from the sequence but
from the sample too, I coloured the UMAP reductions with the cancer types. This allowed
the visualisation of how different cancer types were distributed within the two-dimensional
space. Additional sample information I thought important to check was how the cancer
type, age, sex, and ancestry affected the prediction of the DMM probabilities. I did this
with ordinary least squares regression. I also created boxplots for the distribution of the
sample mean DMM predicted probabilities for the cancer types, and for different age and
sex groups.
I compared the different pathogenicity and functional impact scores against the DMM
probabilities. I did this to see if DMMs probabilities show differences between the likely
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pathogenic mutations versus mutations that are not pathogenic or at least are not known
to be pathogenic. The hypothesis with DMM is that it should do worse in predicting
driver mutations than passenger mutations, because driver mutations happen in unusual
contexts and thus DMM will not learn these mutations as well leading to worse predictions.
In the comparison images the pathogenic classes should show lower DMM probabilities.
Since these scores generally use a higher score to mean more pathogenic there should be
negative correlation between DMM probabilities and the scores. I also compared some of
the scores against each other to see if they agreed with each other on the pathogenicity
of the mutations. SynMICdb and CMC significance tier levels could not be compared
against each other as all synonymous mutations in CMC are ranked as ‘Other’ I did this
kind of comparison also with the hotspot mutations as they should also have lower DMM
probabilities for the hotspot mutations.
The last experiment I ran was one where I used OncodriveFML to see if it could separate
out the known cancer driver genes APC, BRAF, KRAS and TP53 from the other genes I
tested. If DMM works well it should be able to do this if the probabilities work well and
have differences in the probabilities for the true hotspots in them and lower probabilities
for the rest of the gene regions and lower probabilities for the non-cancer genes. I also
compared the DMM probabilities against the CADD scores in their ability to separate the
genes.
4.1 Exploration of the Deep Mutation Modelling out-
put
Basic information on the substitutions
Based on the reference and alternative alleles I classified all mutations into six basic
substitution types and calculated which ones DMM predicted with high accuracy and
which ones had lower accuracy. Table 4.1 contains the percentages of the accurately
predicted substitutions. A mutation is correctly predicted when the probability of the
true mutation ptrue and the highest predicted probability ppred are the same. Based on
the table C→T : G→A substitution is the easiest one to predict correctly. Overall, the
accuracy follows the number of mutations where the higher number of mutations means
higher accuracy with the only exception being C→G : G→C where it has more mutations
that T→G : A→C, but lower accuracy. T→A : A→T on the other hand seems to pose a
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challenge for the DMM models as it has the lowest percentage of correctly classified cases.
Table 4.2 shows that overall the ptrue probabilities are quite low for the substitutions,
but C→T : G→A sticks out as one with higher chance of being predicted as true. As
in Table 4.1, Table 4.2 shows that T→A : A→T has the lowest mean probabilities of it
being predicted correctly. Table 4.2 also shows the mean probability of any mutation and
it shows that the probabilities are much higher than for any of the true mutations, but the
probabilities for any mutation re also much more uniform with less differences between the
substitutions. Overall, the DMM model’s predictions follow the number of substitutions
and in the case of pany the predictions between different substitutions are quite uniform.
Percentage of correctly predicted substitutions and the number of substitutions
Substitution PCAWG correct TCGA correct PCAWG subs. PCAWG % TCGA subs. TCGA %
C→A : G→T 42.5 55.8 105,955 14.3 465,080 18.3
C→G : G→C 13.6 33.4 56,098 7.6 187,775 7.4
C→T : G→A 74.7 73.9 400,022 54.1 1,397,337 54.9
T→A : A→T 11.8 19.4 41,166 5.6 100,705 4.0
T→C : A→G 36.6 53.7 91,532 12.4 271,757 10.7
T→G : A→C 31.3 43.6 44,568 6.0 124,538 4.9
Table 4.1: Percentages of correctly predicted substitutions and the number and percentage of the sub-
stitutions
Mean pany and ptrue for the substitutions
Substitution PCAWG ptrue PCAWG pany TCGA ptrue TCGA pany
C→A : G→T 0.34 0.83 0.42 0.70
C→G : G→C 0.14 0.77 0.28 0.70
C→T : G→A 0.64 0.87 0.58 0.71
T→A : A→T 0.13 0.82 0.21 0.65
T→C : A→G 0.25 0.84 0.39 0.63
T→G : A→C 0.25 0.86 0.32 0.68
Table 4.2: Mean predicted probabilities for the substitutions
The input sequences in the analysis for DMM contain at least one mutation in the centre
of the input sequence, but the sequence may contain more mutations elsewhere in the
sequence. The effect of these mutations according to Figure 4.1 is that the extra mutations
increase DMM’s ability to predict either any mutation or the true mutation. The effect
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is less apparent in the TCGA dataset. Based on Student’s T-test all of the four different
subfigures in Figure 4.1 had statistically significant differences as they all had p-values
close to zero and the test scores were approximately -205.74, -183.25, -46.12, and -61.83.
Figure 4.1: Effect of additional mutations in sequence on pany and ptrue
For basic visualisation of the probability vectors of the different mutations and the com-
bined sample and sequence integrated feature vectors I used UMAP to reduce the dimen-
sionality to two. In Figure 4.2 the individual points are made out of the probability vectors
of the mutations so that the location of an individual point in the image is based on the
probability vector of a mutation. The colour on the other hand is the true mutation of
the same point. Based on Figure 4.2 the probability vectors and the UMAP reduction
separate the six different substitutions into different regions within the UMAP reduction.
C→T : G→A substitutions clearly form their own large regions within the plots.
(a) PCAWG (b) TCGA




The clusters in Figure 4.2 sample and sequence feature vector, right-hand-side subfigures,
UMAP reduction become clearer when they are coloured by cancer types as the different
cancer types are distributed in many cases into their own clusters while others share
clusters. For example melanoma mutations form their own very distinct clusters and
these clusters mostly overlap with C→T : G→A substitutions as can be observed when
comparing Figures 4.2 and 4.3.
(a) PCAWG
(b) TCGA
Figure 4.3: UMAP of the PCAWG and TCGA probability and feature vectors, histology
The separation of melanomas into four distinct clusters in the Figure 4.3a right-hand-
side subfigure is mostly based on the substitution type present in the sequence. Two of
the clusters have mostly C→T : G→A substitutions alongside with a few other C base
reference substitutions while the other two clusters have the T reference substitutions as
can be seen in Figure 4.4. Otherwise, the clusters shared features so that clusters 5 and
12 had similar features and clusters 11 and 16 had similar features.
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Figure 4.4: Clustering of the PCAWG data and substitutions in melanoma clusters
Probability outputs
Using the predicted values of pany, ptrue, and ppred to colour the UMAPs results in the
high probabilities clustering together in the ptrue images as seen in Figure 4.5. When
comparing the images in Figure 4.5 to the real substitutions in Figure 4.2 we can see that
the ptrue has the highest values in the same regions where the C→T : G→A and C→A :
G→T substitutions are. pany on the other hand means that any mutation is possible in
this position. Based on the pany Figures 4.5a and 4.5b the interesting areas are the wedge
shaped regions in the centre of the subfigures on the left as the DMM model predicts that
in these areas no mutation has happened. The ppred and ptrue images for the most part
look similar in Figure 4.5.
Figure 4.6 shows the sample means of pany and ptrue in PCAWG and TCGA datasets.
Each dot is one sample and the colours are the same cancer types as in Figure 4.3. In
Figure 4.6 we can see that the TCGA model is quite flat in the pany subplot and even the
ptrue is not very different between different cancer types. The only exception is the group
that contains skin cutaneous melanomas (light pink) which hover above the rest of the
samples. The PCAWG model shows heavy dependence on the number of mutations in
the pany subplot of Figure 4.6. In this subplot we can clearly see the effect of the number
of mutations on pany so that the higher number of mutations there are the higher the
probability of pany is. The ptrue on the other hand while dependent on the number of
mutations does not rely on it as much. The interesting point in this whole figure is that
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(a) PCAWG pany (b) TCGA pany
(c) PCAWG ptrue (d) TCGA ptrue
(e) PCAWG ppred (f) TCGA ppred
Figure 4.5: UMAP of the PCAWG and TCGA probability and feature vectors, probabilities
TCGA for the most part is flat while PCAWG shows that it is more dependent on the
number of mutations.
Figure 4.7 shows the mean pany and mean ptrue for samples in the PCAWG dataset.
Based on this figure the PCAWG model seems to work the best for melanoma samples
as melanomas have the highest mean pany and ptrue. Based on Figure 4.7 the model may
work well for melanomas from PCAWG, but many of the other cancer have very low ptrue
probabilities. I made a similar image for TCGA but like in Figure 4.6 the model looked
flat and like in PCAWG the melanomas had highest pany and ptrue probabilities.
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Figure 4.6: Mean pany and ptrue in samples compared to the number of mutations in the samples in
TCGA and PCAWG, the colours are the same as in the cancer types
Sex differences in the probability outputs
Figure 4.8 shows sample mean pany and ptrue probabilities for the PCAWG and TCGA
datasets by sex and age group. Figure 4.8a shows that in the PCAWG model the probabil-
ities become higher with age, except for the over 80 groups where it decreases a little again.
This increase in prediction ability is especially notable in pany. The TCGA model on the
other hand looks flat again, but the mean probabilities are higher than in the PCAWG.
The TCGA probabilities on the other hand show a smaller range of probabilities than the
PCAWG model. The TCGA mean pany are between 0.6 and 0.8 while in the PCAWG
there are samples where the mean pany reaches nearly 1. In the ptrue subfigures the outlier
samples that have a mean probability higher than 0.6 are mostly melanomas in both the
PCAWG and the TCGA subfigures.
Ordinary least squares for sample features
I performed an OLS regression on the data where my dependent value was either pany or
ptrue and the independent values were the age and sex of the patient, the ancestry of the




Figure 4.7: PCAWG histology
between the TCGA and PCAWG datasets. For TCGA pany the R2 was 0.04 and for ptrue
it was 0.24. For the PCAWG data the R2 was 0.56 for pany and for ptrue it was 0.49. In all
cases male sex was associated with slight increase in the probabilities but even the highest
coefficient for male sex was only 0.007 in the PCAWG ptrue model. The various cancer
types had different coefficients, but skin melanoma in all models had a positive coefficient.
For the ptrue TCGA model it was 0.28 and for pany it was 0.05. For the PCAWG ptrue
model it was 0.38 and for the pany it was 0.12. Age had different effects in the PCAWG
and TCGA regressions. In PCAWG age had a low but positive coefficient, ptrue 0.0001





Figure 4.8: Probabilities in the PCAWG and TCGA dataset age and sex brackets
4.2 Functional impact and pathogenicity scores
CMC significance tiers
I was also interested in how the CMC mutation significance tier affects the pany and ptrue
values in the PCAWG and TCGA datasets. In both cases I combined the mutations in the
two different datasets based on the position and reference and alternative alleles. Muta-
tions that were present in the TCGA and PCAWG datasets but had no CMC information
were marked as ’NaN’ mutations. The results are shown in Figure 4.9. In Figure 4.9a it
is visible that tier 1 has lower pany and ppred probabilities than the other tiers while in the
ptrue subfigure tiers 1,2, and 3 have closer medians, but the bulk of the tier 1 mutations still
have lower probabilities. According to Student’s T-test all significance triers differed sig-
nificantly from the ‘Other’ category. Between tiers 1,2, and 3 the differences were smaller.
In the pany probabilities the test statistic was -2.80 and p-value 0.005 for tiers 1 and 2
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while between tiers 1 and 3 the test statistic and p-value were -4.07 and 5.183e-05. For
pany there was no significant differences between tiers 2 and 3. There we no significant
differences between tiers 1 and 2 or between tiers 2 and 3 in the ptrue probabilities. There
were some differences between tiers 1 and 3 in the ptrue probability and for that the test
statistic and p-value were -3.15 and 0.002, this difference in the case of ppred was -4.15
and 3.728e-05. For ppred and tiers 1 and 2 the test statistic was -2.29 and the p-value was
0.023.
In the TCGA subfigure 4.9b most of the tiers have similar looking medians and the dif-
ferences do not look as great as the ones in the PCAWG subfigure. Again, in all cases all
tiers were statistically significantly different from the ‘Other’ group. In the case of pany
tiers 1 and 2 the test statistic was 2.95 and the p-value was 0.003, for tiers 1 and 3 the
test statistic was -3.02 and p-value was 0.003. For tiers 2 and 3 the test statistic was -5.76
and the p-value was 3.710e-20. For ptrue the T-test gave the following values for tiers 1
and 2: test statistic was 3.68 and p-value 0.0002 and for tiers 2 and 3 the test statistic
was -2.68 and p-value 0.007. Tiers 1 and 3 had no significant p-value. In the case of ppred
tiers 1 and 2 the test statistic was -2.78 and p-value 0.006. For tiers 1 and 3 it was -7.36
and 2.116e-13. For tiers 2 and 3 it was -2.99 and 0.003.
SynMICdb
Figure 4.10 shows the scatterplots between the SynMICdb score and the DMM probabil-
ities pany, ptrue and ppred. The figures also show a regression model fitted on the data.
The figures in Figure 4.10 show that there exists negative correlation between the DMM
output and the SynMICdb score. PCAWG shows stronger correlation in Figure 4.10a than
TCGA does in Figure 4.10b. The Spearman correlation between the PCAWG pany, ptrue,
ppred, and SynMICdb score were -0.45, -0.49, and -0.46 and they all had p-values close to
zero. For TCGA the same correlations were -0.08, -0.25, and -0.25 and the p-values were
close to zero.
Figure 4.11 shows the mutation probability vector UMAPs coloured by the SynMICdb
score values. Most of the higher scores cluster in the figures within the wedge shaped
regions in the middle of the figures. When comparing these UMAPs to Figures 4.5 it is




Figure 4.9: Probabilities in the PCAWG and TCGA dataset by CMC significance tiers
CADD
I calculated the Spearman’s correlation also between pany and ptrue for CADD scores. For
the PCAWG dataset the correlation between pany and CADD RAW score was -0.02 and
p-value 3.646e-47 and for ptrue they were -0.02 and p-value 3.012e-38. For the TCGA
dataset the correlation between pany was 0.02 and the p-value was 3.185e-130 and for ptrue
it was -0.01 and the p-value was 1.338e-40. The values for CADD PHRED score did not





Figure 4.10: Probabilities in the PCAWG and TCGA dataset vs SynMICdb score
Figure 4.11: UMAP of PCAWG and TCGA colored by SynMICdb score
OncoVar
I also compared the DMM outputs to OncoVar scores. The Spearman’s correlation between
OncoVar mutation level score for PCAWG pany and ptrue were -0.01 with p-value 0.0004
and -0.001 and p-value 0.841. For TCGA the correlations were for pany 0.001 and p-value
0.854 and for ptrue -0.01 and p-value 0.058. For gene level OncoVar score and for PCAWG
gene level mean pany the Spearman’s correlation was 0.04 and the p-value was 4.065e-08
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and for mean ptrue they were -0.01 and 0.245. For TCGA the correlation for mean pany was
-0.01 and the p-value was 0.061 and for mean ptrue the correlation was 0.09 and the p-value
was 4.093e-36. OncoVar also features a consensus score, and I computed the Spearman’s
correlation between it and the gene level mean pany and ptrue probabilities. For PCAWG
the correlation for mean pany was 0.01 and p-value was 0.324 and for ptrue they were 0.01
and 0.261, respectively. For TCGA the correlation for mean pany was -0.03 and p-value
was 4.098e-06 and for mean ptrue they were -0.07 and 3.219e-20.
Figure 4.12 shows the OncoVar driver levels with the mean DMM probability outputs per
gene. In both the PCAWG and TCGA subfigures there is not much visible differences
between the different driver levels in the median values for the probabilities. Level 4 is
the highest level and genes in this category are classified as drivers.
CADD and OncoVar in CMC significance tiers
For comparison’s sake to the DMM probabilities I also made boxplots for the CMC signifi-
cance tiers and instead of the DMM probabilities I used the CADD PHRED and OncoVar
scores. Both had higher median values for the CMC tiers that have some evidence of them
being pathogenic compared to the tier that has no known evidence of being pathogenic.
The effect can be seen in Figures 4.13 and 4.14.
4.3 Score levels of mutation hotspots
I also analysed the DMM pany and ptrue outputs in relation with known cancer hotspots.
Figure 4.15 shows the pany and ptrue values for the known hotspot mutations and mutations
which hotspot status is not known. In both the PCAWG and TCGA subfigures it is
visible that hotspot mutations have lower median probabilities than the mutations for
which hotspot status is not known. Figure 4.16 shows the hotspot mutations in four
known cancer genes TP53, KRAS, APC, and BRAF and their probabilities. In this case
the hotspots are defined simply by the chromosome and position of the mutation. In the
PCAWG subfigures it is visible that the mutations in known hotspot positions have lower
pany than the mutations in not hotspot positions. The same is visible for ptrue except
for TP53 where the probability is higher for known hotspot mutations. In Figure 4.16a
the genes that have somewhat statistically significant differences between the hotspot and
unkown categories are TP53 and KRAS. Their test statistics and p-values from a T-test
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(a) OncoVar driver levels, PCAWG
(b) OncoVar driver levels, TCGA
Figure 4.12: Mean probabilities in the PCAWG and TCGA genes vs OncoVar driver level
are -2.40 and 0.017 for TP53 and -2.03 and 0.043 for KRAS. In the TCGA pany subfigure
the median between the known and unknown hotspot mutations in different genes is more
variable. In TP53 the median is roughly similar. In KRAS and BRAF on the other hand
the pany is higher for known hotpot mutations while in APC it is lower for known hotpot
mutations than for the unknown ones. For the ptrue TP53 is the only gene for which
the median ptrue is higher for the known hotspot mutations than the unknown mutations.
For the other three genes the known hotpot mutations have lower median ptrue. The test
statistic from T-tests indicated that for TCGA the differences were significant for the
genes in the ptrue case and in pany only APC and KRAS are significant.
Additionally, I did this with CADD scores to see if they behave like expected with the
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(a) CMC significance tiers, PCAWG (b) CMC significance tiers, TCGA
Figure 4.13: CADD PHRED in CMC significance tiers for PCAWG and TCGA
(a) CMC significance tiers, PCAWG (b) CMC significance tiers, TCGA
Figure 4.14: OncoVar score in CMC significance tiers for PCAWG and TCGA
hotspots too. The results can be seen in Figure 4.17 and in both subfigures the median is
higher for the mutations in the hotspots than for the unknown mutations.
4.4 OncodriveFML experiment
Figure 4.18 shows the output of the OncodriveFML for all of the scores and genes for the
PCAWG melanoma samples. From the CADD scores in Figures 4.18c and 4.18d it is clear
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(a) PCAWG hotspots (b) TCGA hotspots
Figure 4.15: Hotspots in the PCAWG and TCGA datasets
that the genes TP53 and BRAF have achieved statistical significance as their p-values,
both 1e-06, are the smallest possible ones. APC and KRAS have also small p-values, in
Figure 4.18c 0.037 and 0.042 respectively and in Figure 4.18d 0.034 and 0.028 respectively.
In contrast in 4.18b ptrue only shows BRAF achieving significance with p-value being the
smallest possible one, 1e-06. TP53 also shows some degree of significance as its p-value is
0.024. In 4.18a however, we can see p-value inflation as all of the datapoints float above
the central diagonal line. The diagonal line represents data that is equally distributed. In
this case the p-values for TTN, PCLO and TP53 are 0.003, 0.005, and 0.007 respectively.
In Figure 4.19 it is again visible that the CADD scores achieve much better results as they
are able to separate the known cancer genes from the rest of the genes. KRAS especially
looks like it has very small p-values in the CADD score subplots. The p-values for APC,
BRAF, KRAS and TP53 in Figure 4.19c are 0.055, 0.016, 2e-05, and 0.011 respectively.
In Figure 4.19d they are 0.019, 0.031, 4.9e-05, and 0.005 respectively. Meanwhile the pany
does not result in any gene being considered significant with the exception of TTN, which
has a p-value 0.026. In ptrue subfigure BRAF is again considered significant even if not as
much as KRAS in the CADD subfigures. BRAF however does have smaller p-values in
the ptrue subfigure than in the CADD subfigures. The p-values in Figure 4.19b for BRAF,
TP53, ATR, TTN and KRAS are 0.003, 0.043, 0.050, 0.057, and 0.070.
In Figure 4.20 CADD scores achieve good success but in this case neither of the DMM
scores shows any gene as significant. In the CADD subfigures TP53 is the gene that
achieves smallest p-values. Interestingly GRIN2B is also supposedly significant in the
CADD subfigures. In Figure 4.20c the p-values for TP53, GRIN2B, KRAS and APC are
1e-06, 0.0003, 0.001, and 0.078. In Figure 4.20d they are 1e-06, 0.001, 0.001, and 0.042
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(a) PCAWG hotspots pany
(b) PCAWG hotspots ptrue
(c) TCGA hotspots pany
(d) TCGA hotspots ptrue
Figure 4.16: Hotspots in four cancer genes in the PCAWG and TCGA datasets
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Figure 4.17: Hotspots with CADD PHRED score for TCGA and PCAWG
respectively.
Figure 4.21 shows that in the CADD score subfigures almost all genes supposedly have
significant p-values with the exceptions being TTN and ATR. In these figures TP53,
PCLO, KRAS, GRIN2B and BRAF all have the minimum p-value 1e-06. In Figure 4.21a
three of the known cancer genes APC, KRAS, and TP53 separate above the main bulk
of the genes even if they do not have very significant p-values. Their p-values are in this
figure 0.067, 0.032, and 0.016. In Figure 4.21b all of the known four cancer genes have
separated themselves from the main bulk of the genes and BRAF achieves very good p-
values while KRAS has somewhat worse but still okay looking p-value. The p-values for
BRAF, KRAS, APC and TP53 in this subfigure are 1e-06, 0.0001, 0.013, and 0.049.
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(a) DMM pany (b) DMM ptrue
(c) CADD PHRED (d) CADD RAW
Figure 4.18: The comparison between DMM scores and CADD scores in PCAWG Skin-Melanoma
samples
62
(a) DMM pany (b) DMM ptrue
(c) CADD PHRED (d) CADD RAW
Figure 4.19: The comparison between DMM scores and CADD scores in PCAWG MSI samples
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(a) DMM pany (b) DMM ptrue
(c) CADD PHRED (d) CADD RAW
Figure 4.20: The comparison between DMM scores and CADD scores in TCGA hepatocellular carcino-
mas
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(a) DMM pany (b) DMM ptrue
(c) CADD PHRED (d) CADD RAW
Figure 4.21: The comparison between DMM scores and CADD scores in TCGA melanoma
5 Discussion
5.1 Commentary on individual results
The results shown in Tables 4.1 and 4.2 show that the more common a substitution is
the higher the percentage of correctly predicted mutations and the higher the predicted
probabilities are. This is likely due to the fact that the number of mutations in the test
sample reflect the proportions of the mutations in the training set and because of this
the model gets exposed to a higher number of common mutations and it becomes better
at predicting these over the rarer mutations. Similarly Figure 4.1 shows that sequences
with more than one mutation have higher predicted probabilities might be due to the fact
that the model sees these regions with multiple mutations close by multiple times and the
model thus might start learning these regions more compared to other regions. Overall, the
result of more common mutations having higher predicted probabilities is not surprising
in this light. The substitutions that C→T : G→A and that C→A : G→T especially show
this effect where the large number of these mutations have made them easy to predict.
The regions in Figure 4.2 which contains these substitutions overlaps with the regions for
high ptrue in Figure 4.5.
In the UMAPs in Figures 4.2, 4.3 and 4.5 it is visible that C→T : G→A substitutions
tend to be located in the same regions as melanoma samples and high values for ptrue.
This is not surprising as shown in Tables 4.1 and 4.2 these substitutions are predicted
correctly often, and they have the highest mean ptrue values. These substitutions are also
very common in melanomas and this can be observed from the fact that the regions for
these substitutions overlap, for the most part, with the regions for melanoma samples.
It is not surprising then that in Figures 4.7a and 4.7b that melanoma samples have the
highest mean pany and ptrue out of the cancer types for PCAWG. Both in the PCAWG
and TCGA datasets melanoma samples have the most mutations as seen in Figure 3.4
and based on Figure 4.6 that the number of mutations in melanomas has made predicting
probabilities for mutations in melanoma easier compared to other cancer types. Especially
based on Figure 4.6 the PCAWG models predictive ability is dependent on the number
of mutations while the same effect is not seen in the TCGA model. While the different
cancer types in TCGA have different number of mutations this seems to have little effect
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on the predicted probability of pany or ptrue and instead the probabilities are close to each
other.
It is difficult to say if the flatness of the TCGA model is because it has gotten enough
examples from every substitution type to predict them all well or if there is something
wrong with the model. Nevertheless, in almost all cases the TCGA model has smaller
differences between the predicted probabilities for the mutations. According to the OLS
regression the sample features age, sex, ancestry, and cancer type do not explain that
much of the variance either when it comes to the TCGA model. It is possible that the
TCGA model leans more towards the sequence features. On the other hand, according to
OLS these sample features explain approximately half of the variance in PCAWG data.
In Figure 4.4 there are four melanoma clusters that the model has formed. In this case the
clusters are mostly split into them based on the substitution type, but they are also split
into these clusters based on their features. Clusters 5 and 12 resembled each other based
on their features and 11 and 16 resembled each other. For example, the age distributions
were similar to each other in the pairs and dissimilar to the other pair. Other features
such as the top principal components of the sample information also showed this same
split into pairs. The exact reasons for this split were hard to parse out and I could not
form coherent patient profiles or groups out of the clusters.
Similarly, to the cancer types the age and sex affect the number of mutations in the
samples and thus affect the mean pany and ptrue in these same groups. The sex difference
was visible in OLS too as the sample being from a male increased the probabilities slightly,
but this is probably because there were more male samples to begin with. In Figure 3.3 it
is visible that older age groups have higher number of mutations and at least in the case
of PCAWG in Figure 4.8a the mean probabilities are also affected by age. In the 25-45
and 45-60 age groups females have more mutations and higher predicted probabilities than
males of the same ages. Here we can see the effect of the number of mutations on the
probability outputs.
The CMC boxplots in Figure 4.9 are interesting as the hypothesis regarding driver muta-
tion prediction with DMM is that the driver mutations should be harder to predict. In
these pictures it is clearly visible that the more pathogenic tiers have lower probabilities
than the ‘Other’ tier that contains mutations that are not known to be pathogenic. Espe-
cially the PCAWG results looked promising as the difference between the medians between
the pathogenic tiers and the ‘Other’ tier were large and especially for tier 1, which has the
most evidence for being pathogenic. The differences between medians are not as great in
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the TCGA model and the predicted probabilities are again quite flat. Interestingly in the
TCGA model tier 2 mutations had lower median probability than tier 1 mutations. Simi-
larly in Figure 4.10 the SynMICdb score correlates better with the PCAWG model than
with the TCGA model probabilities. With PCAWG the correlation is quite strong too
and the interpretation from the scatterplots would be that when the predicted probability
increases then the potential functional impact of the synonymous mutation lessens. The
same idea behind the driver mutations applies here, mutations that have high functional
impact are rare and thus it is hard to predict them. In Figure 4.11 most of the SynMICdb
mutations that have a higher score seem to cluster around the wedge shaped regions that
have in Figure 4.5 lower values for pany and ptrue as can also be seen from the scatterplots.
These regions in the Figure 4.11 are also not as clearly dominated by a certain substitution
or by any one cancer type as seen in Figure 4.2.
Interestingly OncoVar and CADD diverge from this hypothesis that driver mutations are
harder to predict. CADD had no significant correlation for either pany or ptrue in either
the PCAWG or the TCGA dataset. OncoVar did not exhibit correlation with the datasets
either. Interestingly in Figures 4.13 and 4.14 the differences between the significance tiers
are quite strong and especially in the case of OncoVar score.
The hotspot figures 4.15 and 4.16 seem to support the hypothesis again that driver mu-
tations are harder to predict if we consider the hotspot mutations to be likely driver
mutations. CADD also behaves as expected in hotspots in Figure 4.17 as the hotspots
have a higher median score. In this case I considered only the hotspot positions instead
of the exact mutations as there were many mutations that were in the hotspot positions
but did not have the exact same alleles. The mutations in known hotspot had overall
lower medians for the predicted probabilities than the mutations that are not located in
the hotspot loci. In PCAWG the median pany was also lower in the Figure 4.16a for the
four cancer genes. However, in the case of ptrue for the hotspots in Figure 4.16b TP53 has
a higher median for hotpots than for unknown mutations, which could be because In the
case of TP53 the specific hotpot mutations might be so common that the DMM model
simply learns these mutations, while for KRAS it is hard to say which group has a higher
median for ptrue. The other two genes have lower medians for the hotspot mutations.
In Figure 4.16c only APC hotspot mutations have a clearly lower median pany than the
unknown mutations do. On the other hand in the case of ptrue, TP53 was the only gene
that had higher median ptrue for the hotspot mutations than the unknown mutations
as seen in Figure 4.16d. For the other three genes the median was lower for the hotspot
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mutations. The flatness of the TCGA model is visible here too as the hotpot and unknown
groups’ median values became more similar.
Finally, I performed OncodriveFML analysis of the different genes for the four cancer types.
Figure 4.18 shows the results for PCAWG melanomas. In the PCAWG Skin-Melanoma
genes it was most striking how there is p-value inflation in the pany based score analysis
as all of the gene points start to rise and hover over the line of expected values as seen in
Figure 4.18a. By Contrast the ptrue based score works much better as most of the genes
end up being only slightly above the line of expected values. BRAF also shows up in the
ptrue figure with a very significant p-value as it reached the smallest possible value as seen
in Figure 4.18b. The CADD values seem to work better than the DMM based scores as
they identify both BRAF and TP53 as significantly mutated genes with very low p-values
as seen in Figures 4.18d and 4.18c. In this case the DMM scores likely need some kind of
adjustment by either training the model again or there might need to be more samples as
the number of observed mutations for the PCAWG melanoma were quite low as shown in
Table 3.1. The TCGA melanoma dataset had many more mutations within the regions
and overall worked better in OncodriveFML so more samples might be what is needed.
On the other hand, the opposite is seen in TCGA skin cutaneous melanoma where the
CADD scores seem to rate all genes as significant even though only four of them are
supposed to be cancer genes as seen in Figures 4.21d and 4.21c. The pany based score
does not seem to work all that well according to subfigure 4.21a here either as most of
the p-values the cancer genes get are not that significant and BRAF is not significant
at all even though it would be expected for it to be as it is very commonly mutated in
skin cancers. It does become significant when observing Figure 4.21b where ptrue score
was used and it achieves very good p-values. Figure 4.21b is also interesting as it is the
only one where the OncodriveFML has managed to separate all of the four known cancer
genes from the other genes even if it does not give them very significant p-values. Only
BRAF and perhaps KRAS seem like they would have significance. Interestingly here the
TCGA model seems to perform better than the PCAWG model even though in most cases
the TCGA model seems to have had trouble differentiating between more pathogenic and
benign mutations. This, however, could also be due to the TCGA dataset having more
observed mutations available for melanomas than the PCAWG dataset does.
In Figure 4.19 we can see that for the MSI samples with PCAWG pany score that the score
does not work at all as all of the genes are around the line for expected values. The ptrue
score does not work all that great either while the CADD scores are able to separate out
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the four cancer genes. Even CADD does not seem to work all that well in significance of
the genes with the major exception being KRAS. In this case the analysis likely suffered
from only having very few observable mutations within these genes.
Similarly, TCGA hepatocellular carcinoma samples only had very few mutations which
likely caused issues in the analysis. In Figure 4.20 it is observable that the DMM based
scores did not work but at least the genes are around the line for expected values rather
than suffering from p-value inflation. Even the CADD scores seem to have had some issues
with the analysis as the only cancer gene to get very significant p-values is TP53, while
they identified other genes as likely significant most of them do not seem to have very high
p-values.
Overall, it seems that DMM score can be used as a score in OncodriveFML but the exact
way the score is constructed starting from the DMM model training is going to need some
work. Larger mutational datasets are also likely to work better for the analysis as a lot of
the genes had very few observable mutations.
5.2 Research objective fulfillment
Currently, DMM features are only based on the sample and sequence information. The
basic features of DMM indicate that the models might be quite dependent on the number
of example mutations used during training. The indicators for this are the substitutions
that have the highest predicted probabilities are also the more common ones in the datasets
and as these same datasets are used for training the distribution of training examples are
likely very similar. Additional support for this is that the more mutations there are in
a cancer type the higher the predicted probabilities are for it and this applies to other
features too such as the sex of the patient from which the sample is from. The fact that
the sequences which contain an extra mutation have higher probabilities also supports this
conclusion as the DMM model is more likely to see these regions often during the training
process and it might learn the features in these regions better. It is also possible that the
sequence length used affects the outcomes as the model for PCAWG data used sequences of
length 2048 base pairs while the TCGA model used 256 base pairs. The longer sequences
in PCAWG model may contribute to the higher predicted values of the sequences with
extra mutations as the longer sequences mean that the training regions of the different
mutations may result in greater overlap between different the training examples.
The dimensionality reduction of the DMM outputs shows that the predicted mutations
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and cancer types tend to cluster towards similar data points near them. This results in
the same type of substitutions being close to each other. As the spectrum of substitutions
varies between different cancer types the different cancer types also tend to cluster around
each other and they also cluster based on the substitution type. For example, many of
the cancer types form multiple clusters in Figures 4.3 and melanomas form the clearest
separate clusters. These clusters consist almost completely of melanoma mutations. The
main differences between these clusters seems to be the substitution type, but there are
also some other unknown features that separate them. The effect is that these clusters
tend to have different age distributions and other features. Since the UMAP reductions
are based on the mutation probabilities it is expected that the probabilities pany, ptrue and
ppred tend to cluster around mutations that have similar probabilities and where C→T
substitutions also tend to cluster.
Since current ways of scoring mutations’ functional impact and pathogenicity are mostly
the same for every cancer type and patient DMM could provide a method for making more
customisable scores. As the DMM scores depend on the sample features this means that
it can consider the cancer type, sex, age, and other features from the tumour as something
that may influence the probability of the mutation. CMC significance tiers, CADD, and
SynMICdb all have the same scores for every cancer type which means that they may
not fit all cancer types or even individual tumours equally well. OncoVar has cancer type
specific data available that was not analysed here. There are also other limitations on
these scores such as the fact that CMC significance tiers assign all synonymous mutations
as not significant and SynMICdb only works for synonymous mutations.
DMM interacted as expected with the CMC significance tiers and with SynMICdb. As
DMM should be worse at predicting driver mutations it was expected that it should have
lower values for the higher CMC significance tiers, though the effect was quite weak for the
TCGA mutations. Similarly, the expected negative correlation existed between SynMICdb
score and the DMM probabilities as the more pathogenic synonymous mutations should
have lower DMM probabilities while they at the same time have high SynMICdb score.
The mutations that had higher SynMICdb scores also clustered in the same regions as
lower pany and ptrue values in the UMAP reductions as can be seen in Figures 4.5 and
4.11. DMM thus, should be able to find pathogenic synonymous mutations and not just
non-synonymous mutations. CADD and OncoVar on the other hand did not work as
expected. CADD should also exhibit negative correlation with the DMM probabilities,
but it does not. The same can be observed with the OncoVar score and driver levels. When
71
using the CADD PHRED or OncoVar scores for the mutations in the CMC significance
tiers they do behave as expected in that the tiers ranked as having some evidence for
being drivers have higher medians than the ’Other’ tier as can be observed from Figures
4.13 and 4.14. The issues with OncoVar may have been technical if the mutations did
not combine together correctly. The hotspot mutation analysis worked as expected with
DMM the mutations that are in hotspots have lower predicted probabilities than the ones
that are not in known hotspots. CADD works as expected too in these hotspots too, as
it has higher values in the hotspots than in the unknown ones. In general, DMM worked
as expected except for CADD and OncoVar scores. It does not currently seem like DMM
would be competitive as the other scores seem to predict the pathogenicity better, but
DMM could be improved by adjusting the training and by adding epigenetic information
to its modules. The training might need to be adjusted to consider different mutation
clusters, recurrencies of driver mutations, and hypermutational processes present in large
number of tumours. Epigenetics would likely improve the model as epigenetic features can
explain large parts of the mutation density in different genomic regions.
DMM overall performed differently in the four different cancer datasets in the Onco-
driveFML analysis. Overall, ptrue seems to work better than pany in separating out the
true cancer genes. CADD however consistently outperformed DMM in this. Thus, while
DMM probabilities can be used in OncodriveFML in its current form it does not have the
necessary power to separate the cancer genes from other genes. DMM’s predictive power
could be improved by either altering the DMM model itself or by altering the way the
score file was created as now the mutations that had a zero probability were assigned the
lowest non-zero probability found from the same sample and gene. If the probabilities
were kept as close to zero as possible it might improve the analysis.
6 Conclusion
Cancer is one of the leading causes of death in the world and as its incidence is expected
to increase it is critical to understand what causes it. Understanding cancer better will
lead to better outcomes for the patients. As our understanding of cancer has grown it
has led to understanding that cancer is not a single disease, but a group of disease caused
by similar mechanisms. The cause of cancer is thought to be driver mutations that lead
to the uncontrolled expansion of a somatic cell growth that ends up forming a tumour.
The driver mutations can differ between cancers, so it is crucial to understand the driver
mutation profiles of different cancer types. However, even then there is still the level of
individual tumours and their mutation profiles. For the best results in cancer treatment
understanding individual tumours would be ideal.
Driver mutations can be classified into non-synonymous, synonymous, mini, and non-
coding driver mutations depending on what kind of mutation it is. Non-synonymous
mutations are the most studied out of these groups. Most of the driver discovery methods
and scores have been developed for the non-synonymous mutations. Most of these methods
have focused on searching recurrent missense mutations. These same methods have often
considered synonymous mutations as neutral events even though there is evidence that
this is not always so. This focus on the coding regions is however somewhat limiting as
most of the human genome is non-coding and most mutations are bound to happen there.
Therefore, it is important to develop methods for driver discovery that can also function
in the non-coding genome and can also work on both synonymous and non-synonymous
mutations. Deep Mutation Modelling, DMM, is a deep neural network based methods for
predicting the probability of mutations. As it is a deep learning based method it can work
on any region of the genome as long as sufficient examples are available for the training.
Deep learning methods can learn directly from the data so human aid in discovering fea-
tures is not needed. DMM thus should be able to learn what kind of mutation contexts
surround driver mutations and what kind of contexts surround passenger mutations. As
driver mutations are rarer than passengers its ability to predict drivers should be worse.
This was demonstrated by the fact that DMM probabilities were worse for mutations that
have been identified by Cancer Mutation Census to be pathogenic, or by a hotspot anal-
ysis to be in hotspots. The same effect was seen with synonymous mutations where more
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pathogenic synonymous mutations have lower DMM probabilities. This effect, however,
was not observed with all compared pathogenicity scores. DMM still shows promise in this
area but it requires improvements to increase its predictive power. Besides just predicting
possible mutations the DMM output can be used as a score in other methods. Onco-
driveFML is one such method where DMM can be used. However, just as with the driver
mutation probabilities DMM does not have enough predictive power to work reliably with
OncodriveFML yet.
Overall, DMM is a potentially useful method for scoring mutations anywhere in the genome
for multiple different mutation types. As it works with individual tumour samples it can
bring studying cancer mutations one step closer to personalised medicine.
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